<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fluvoxamine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fluvoxamine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fluvoxamine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8474" href="/d/html/8474.html" rel="external">see "Fluvoxamine: Drug information"</a> and <a class="drug drug_patient" data-topicid="12495" href="/d/html/12495.html" rel="external">see "Fluvoxamine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708808"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Suicidality and antidepressant drugs:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants increased the risk compared with placebo of suicidal thinking and behavior (suicidality) in short-term studies in children, adolescents, and young adults with major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of fluvoxamine in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared with placebo in adults older than 24 years; there was a reduction in risk with antidepressants compared with placebo in adults 65 years and older. Depression and certain other psychiatric disorders are associated with increases in the risk of suicide. Closely observe and appropriately monitor patients of all ages who are started on therapy for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication with the health care provider. Fluvoxamine immediate release is not approved for use in pediatric patients, except for patients with obsessive-compulsive disorder (OCD). Fluvoxamine extended release (ER) has not been evaluated in pediatric patients.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866960"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Fluvoxamine;</li>
<li>APO-Fluvoxamine;</li>
<li>Luvox;</li>
<li>RIVA-Fluvox [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1014951"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidepressant, Selective Serotonin Reuptake Inhibitor (SSRI)</span></li></ul></div>
<div class="block dop drugH1Div" id="F173619"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In the management of pediatric depression in adolescents, if pharmacotherapy deemed necessary with/without psychotherapeutic interventions, a selective serotonin reuptake inhibitor (SSRI) is recommended first line; fluvoxamine is not recommended first line due to the availability of 2 SSRIs with FDA approval for pediatric depression (fluoxetine, escitalopram) and the need for multiple doses a day. Fluvoxamine clinical trial evidence in adolescents is sparse; dosing based on expert recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29483201','lexi-content-ref-APA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29483201','lexi-content-ref-APA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Immediate release: Oral: Initial: 25 to 50 mg once daily at bedtime; titrate in 50 mg increments (if initial daily dose 25 mg/day used, smaller titration increments may be necessary initially) at 1- to 2-week intervals; usual effective daily dose: 150 mg/day; maximum daily dose: 300 mg/<b>day</b>; daily doses &gt;50 mg should be divided into 2 doses; if applicable, administer larger portion of daily dose at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29483201','lexi-content-ref-23881712','lexi-content-ref-30397569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29483201','lexi-content-ref-23881712','lexi-content-ref-30397569'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5359f530-bf85-41b9-82bc-913f7d455fcc">Obsessive-compulsive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Obsessive-compulsive disorder (OCD):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In the management of OCD in children and adolescents, if pharmacotherapy deemed necessary, it should be in combination with cognitive behavioral therapy (CBT) and an SSRI should be used first line; a preferred agent has not been identified (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22176943','lexi-content-ref-15507582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22176943','lexi-content-ref-15507582'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release:</p>
<p style="text-indent:-2em;margin-left:6em;">Children 8 to 12 years: <b>Note</b>
<b>:</b> Pharmacokinetic age-related and gender-related differences may affect doses at which therapeutic benefit is observed (see "Pharmacokinetics: Additional Considerations").</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: Initial: 12.5 to 25 mg once daily at bedtime; titrate in 25 mg increments at 7- to 14-day intervals to therapeutic effect; longer titration intervals may be necessary in some patients to minimize risk of behavior activation. Usual daily dosage range: 50 to 200 mg/day; daily doses &gt;50 mg should be divided into 2 doses; if applicable, administer larger portion of daily dose at bedtime. Maximum daily dose: Children: 8 to 11 years: 200 mg/<b>day</b>; Children 12 years of age: 300 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22176943','lexi-content-ref-31447707','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22176943','lexi-content-ref-31447707','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: Initial: 25 to 50 mg once daily at bedtime; titrate in 25 mg increments at 7- to 14-day intervals to therapeutic effect; longer titration intervals may be necessary in some patients to minimize risk of behavior activation. Usual daily dosage range: 50 to 200 mg/day; daily doses &gt;50 mg should be divided into 2 doses; if applicable, administer larger portion of daily dose at bedtime. Maximum daily dose: Adolescents: 300 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22176943','lexi-content-ref-31447707','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22176943','lexi-content-ref-31447707','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Limited data available: Children ≥8 years and Adolescents: Oral: Not for initial therapy; use the immediate-release formulation to initiate and titrate therapy; once patient is on a stable daily dose, convert to the extended-release formulation at same total daily dose and administer once daily if an appropriate mg-strength dosage form is available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Consider planning discontinuation of therapy during lower-stress times, recognizing nonillness-related factors could cause stress or anxiety and be misattributed to treatment discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29337001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29337001'])">Ref</a></span>). Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of discontinuation syndromes (withdrawal) and allow for the detection of reemerging disease state symptoms (eg, relapse). Evidence supporting ideal taper rates after illness remission is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks, with consideration given to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. After long-term (years) antidepressant treatment, WFSBP guidelines recommend tapering over 4 to 6 months, with close monitoring during and for 6 months after discontinuation. If intolerable discontinuation symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-12479080','lexi-content-ref-19621834','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-12479080','lexi-content-ref-19621834','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51112214"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Limited data suggest fluvoxamine does not accumulate in patients with renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F51112215"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥8 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling. Limited data suggest fluvoxamine clearance is reduced in patients with hepatic impairment. Some experts recommend a maximum daily dose of 150 mg/day in adult patients with moderate-severe hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25248846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25248846'])">Ref</a></span>).</p></div>
<div class="block doa drugH1Div" id="F173604"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8474" href="/d/html/8474.html" rel="external">see "Fluvoxamine: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Some experts suggest a lower starting dose of 25 mg daily and gradual titration in increments of ≤25 mg, particularly in patients with anxiety who are sensitive to antidepressant-associated overstimulation effects (eg, anxiety, insomnia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1','lexi-content-ref-11270909','lexi-content-ref-10753007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1','lexi-content-ref-11270909','lexi-content-ref-10753007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Fluvoxamine IR and ER formulations are interchangeable on a mg-to-mg basis. For the IR formulation, divide total daily doses &gt;100 mg into twice-daily dosing.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d98a9598-5db0-4f0c-a3c4-96cdecc00d76">Binge eating disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Binge eating disorder (off-label use):</b>
<b>Oral:</b> Immediate release: Initial: 50 mg once daily; increase dose based on response and tolerability up to 300 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9842788']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9842788'])">Ref</a></span>). Divide total daily doses &gt;100 mg into twice-daily dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>); dosing frequencies of 3 times daily have also been used in a clinical trial with total daily doses of 300 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11598429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11598429'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="09d5012d-4c68-41f6-9a1f-54da08b78eeb">Bulimia nervosa</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bulimia nervosa (off-label use):</b>
<b>Oral:</b> Immediate release: Initial: 50 mg once daily; increase dose based on response and tolerability up to 300 mg/day, dividing total daily doses &gt;100 mg into twice-daily dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7477802','lexi-content-ref-8834413','lexi-content-ref-9211569','lexi-content-ref-16236688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7477802','lexi-content-ref-8834413','lexi-content-ref-9211569','lexi-content-ref-16236688'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3acdc9e2-eb5e-47b3-8f22-12bd8ae32922">Generalized anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Generalized anxiety disorder (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release</i>: <b>Oral: </b>Initial: 50 mg once daily; increase daily dose in 25 to 50 mg increments based on response and tolerability every ≥3 days up to a therapeutic dose of 100 mg/day; after 4 to 6 weeks, may continue increasing dose in 50 mg increments every 1 to 2 weeks up to a maximum dose of 300 mg/day. Divide total daily doses &gt;100 mg/day into 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1','lexi-content-ref-Hirsch.1','lexi-content-ref-11270909','lexi-content-ref-10753007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1','lexi-content-ref-Hirsch.1','lexi-content-ref-11270909','lexi-content-ref-10753007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release</i>: <b>Oral: </b>Use IR tablets to determine a stable daily dose and then convert to once daily extended release at same total daily dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (off-label use):</b>
<b>Oral:</b> Immediate release: Initial: 50 mg once daily; increase dose based on response and tolerability to usual dosage range of 100 to 200 mg/day, dividing total daily doses &gt;100 mg into twice-daily dosing; doses as high as 300 mg/day have been studied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20238342','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20238342','lexi-content-ref-23879318'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5359f530-bf85-41b9-82bc-913f7d455fcc">Obsessive-compulsive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Obsessive-compulsive disorder:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 50 mg once daily at bedtime; may increase in 50 mg increments at 4- to 7-day intervals, as tolerated; usual dose range: 100 to 300 mg/day, dividing total daily doses &gt;100 mg into twice-daily dosing; maximum dose: 300 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: <b>Oral:</b> Initial: 100 mg once daily at bedtime; may increase in 50 mg increments at intervals of at least 1 week; usual dosage range: 100 to 300 mg/day; maximum dose: 300 mg/day</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="35322c81-c95a-4c47-baaf-72001a1c63ee">Panic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Panic disorder (off-label use):</b>
<b>Oral:</b> Immediate release: Initial: 25 to 50 mg once daily; titrate gradually based on response and tolerability; usual dosage range: 100 to 200 mg/day, dividing total daily doses &gt;100 mg into twice-daily dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.3','lexi-content-ref-11472786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.3','lexi-content-ref-11472786'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33aa39f3-80b9-497a-8725-78dfd54c167a">Posttraumatic stress disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Posttraumatic stress disorder (PTSD) (off-label use): Oral:</b> Immediate release: 75 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16633143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16633143'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24aa5a69-6727-4715-b53a-79a3f9ae11c6">Social anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Social anxiety disorder (off-label use):</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: Initial: 50 mg once daily; may increase in 50 mg increments at intervals of at least 1 week, dividing total daily doses &gt;100 mg into twice-daily dosing; usual dosage range: 100 to 300 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16573847']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16573847'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Initial: 100 mg once daily at bedtime; may be increased in 50 mg increments at intervals of at least 1 week; usual dosage range: 100 to 300 mg daily; maximum dose: 300 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15206657','lexi-content-ref-14604447','lexi-content-ref-14709947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15206657','lexi-content-ref-14604447','lexi-content-ref-14709947'])">Ref</a></span>)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Discontinuation of therapy:</b></i>When discontinuing antidepressant treatment that has lasted for &gt;3 weeks, gradually taper the dose (eg, over 2 to 4 weeks) to minimize withdrawal symptoms and detect reemerging symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-25677972'])">Ref</a></span>). Reasons for a slower taper (eg, over 4 weeks) include prior history of antidepressant withdrawal symptoms or high doses of antidepressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-Hirsch.2019'])">Ref</a></span>). If intolerable withdrawal symptoms occur, resume the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601'])">Ref</a></span>). Select patients (eg, those with a history of discontinuation syndrome) on long-term treatment (&gt;6 months) may benefit from tapering over &gt;3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25677972'])">Ref</a></span>). Evidence supporting ideal taper rates is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601','lexi-content-ref-25677972'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Switching antidepressants: </i></b>Evidence for ideal antidepressant switching strategies is limited; strategies include cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant) and direct switch (abruptly discontinuing the first antidepressant and then starting the new antidepressant at an equivalent dose or lower dose and increasing it gradually). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches, but is contraindicated when switching to or from a monoamine oxidase inhibitor (MAOI). A direct switch may be an appropriate approach when switching to another agent in the same or similar class (eg, when switching between 2 selective serotonin reuptake inhibitors), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, pharmacodynamics), and the degree of symptom control desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.1','lexi-content-ref-23459282','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.1','lexi-content-ref-23459282','lexi-content-ref-23879318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching to or from an MAOI:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing an MAOI and initiation of fluvoxamine.</p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing fluvoxamine and initiation of an MAOI.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991487"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling. Limited data suggest fluvoxamine does not accumulate in patients with renal impairment.</p></div>
<div class="block doha drugH1Div" id="F50988839"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use lower initial doses and titrate slowly; use with caution. Some experts recommend a maximum dose of 150 mg in patients with moderate to severe hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25248846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25248846'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F58527558"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Activation of mania or hypomania</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants (when used as monotherapy) may precipitate a mixed/manic episode in patients with bipolar disorder. Treatment-emergent <b>manic reaction</b> or <b>hypomania</b> have been reported in adult patients with obsessive compulsive disorder and/or unipolar major depressive disorder (MDD) (many cases of bipolar disorder present in episodes of MDD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059','lexi-content-ref-9387089','lexi-content-ref-8305775','lexi-content-ref-1770160','lexi-content-ref-8923100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059','lexi-content-ref-9387089','lexi-content-ref-8305775','lexi-content-ref-1770160','lexi-content-ref-8923100'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; idiosyncratic. Unclear to what extent mood switches represent an uncovering of unrecognized bipolar disorder or a more direct pharmacologic effect independent of diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059','lexi-content-ref-28558366','lexi-content-ref-26667012','lexi-content-ref-19958306']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059','lexi-content-ref-28558366','lexi-content-ref-26667012','lexi-content-ref-19958306'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; a systematic review observed that the risk of switching increased significantly within the initial 2 years of antidepressant treatment in patients with unipolar MDD receiving an antidepressant as monotherapy, but not thereafter (up to 4.6 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depressive episode with psychotic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age at onset of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15289250','lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15289250','lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antidepressant resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32215771','lexi-content-ref-29873955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32215771','lexi-content-ref-29873955'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bleeding risk</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs), including fluvoxamine, may increase the risk of bleeding in adults and pediatric patients, particularly if used concomitantly with antiplatelets and/or anticoagulants. Multiple observational studies have found an association with SSRI use and a variety of bleeding complications, ranging from bruising, hematomas, petechiae,<b> purpuric disease</b> and <b>epistaxis,</b> to <b>cerebrovascular accident</b>, upper <b>gastrointestinal hemorrhage</b>, intracranial hemorrhage, <b>abnormal uterine bleeding</b>, and intraoperative bleeding, although conflicting evidence also exists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23699725','lexi-content-ref-30081645','lexi-content-ref-29536379','lexi-content-ref-28577352','lexi-content-ref-24314591','lexi-content-ref-10755580','lexi-content-ref-8946088','lexi-content-ref-14581256','lexi-content-ref-18460039','lexi-content-ref-27834194','lexi-content-ref-28766108']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23699725','lexi-content-ref-30081645','lexi-content-ref-29536379','lexi-content-ref-28577352','lexi-content-ref-24314591','lexi-content-ref-10755580','lexi-content-ref-8946088','lexi-content-ref-14581256','lexi-content-ref-18460039','lexi-content-ref-27834194','lexi-content-ref-28766108'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Possibly via inhibition of serotonin-mediated platelet activation and subsequent platelet dysfunction. Fluvoxamine is considered to display moderate affinity for the serotonin reuptake receptor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18188866']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18188866'])">Ref</a></span>). SSRIs may also increase gastric acidity, which can increase the risk of GI bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30081645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30081645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; bleeding risk is likely delayed for several weeks until SSRI-induced platelet depletion becomes clinically significant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21190637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21190637'])">Ref</a></span>); although the onset of bleeding may be more unpredictable if patients are taking concomitant antiplatelets, anticoagulants, or nonsteroidal anti-inflammatory drugs (NSAIDs). For upper GI bleeding, some studies have found risk to be the highest in the first 28 to 30 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19716436','lexi-content-ref-19491861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19716436','lexi-content-ref-19491861'])">Ref</a></span>); whereas, another study reported a median time of onset of 25 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17919277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17919277'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of anticoagulants and/or antiplatelets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36208621','lexi-content-ref-21948719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36208621','lexi-content-ref-21948719'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting platelet dysfunction or coagulation disorders (eg, von Willebrand factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27508501','lexi-content-ref-17506225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27508501','lexi-content-ref-17506225'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of NSAIDs increases the risk for upper GI bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777151'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fragility fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Limited data from observational studies involving mostly adults ≥50 years suggest selective serotonin reuptake inhibitors (SSRIs) are associated with an increased risk of bone fractures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22638709','lexi-content-ref-17242321','lexi-content-ref-22659406']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22638709','lexi-content-ref-17242321','lexi-content-ref-22659406'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time-related; mechanism not fully elucidated; postulated to be through a direct effect by SSRIs on bone metabolism via interaction with 5-HT and osteoblast, osteocyte, and/or osteoclast activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22659406','lexi-content-ref-30775508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22659406','lexi-content-ref-30775508'])">Ref</a></span>). An increased tendency for falls may also contribute to the increased risk of fractures associated with SSRIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22638709','lexi-content-ref-18219438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22638709','lexi-content-ref-18219438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; risk appears to increase after initiation and may continue to increase with long-term use. A meta-analysis found risk of fracture increased from 2.9% over 1 year to 5.4% over 2 years; within 5 years, risk increased to 13.4% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30247774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30247774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Long-term use may be a risk factor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20703452','lexi-content-ref-30247774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20703452','lexi-content-ref-30247774'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyponatremia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors are associated with syndrome of inappropriate antidiuretic hormone secretion (<b>SIADH</b>) and/or <b>hyponatremia</b> (including severe cases), predominantly in the elderly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25262043','lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25262043','lexi-content-ref-16896026'])">Ref</a></span>). Hyponatremia is reversible with discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8804257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8804257'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> May cause SIADH via release of antidiuretic hormone (ADH) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>) or may cause nephrogenic SIADH by increasing the sensitivity of the kidney to ADH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; usually develops within the first few weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12086550','lexi-content-ref-19829765','lexi-content-ref-16896026','lexi-content-ref-9241009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12086550','lexi-content-ref-19829765','lexi-content-ref-16896026','lexi-content-ref-9241009'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19829765','lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19829765','lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lower baseline serum sodium concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of hyponatremia (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Symptoms of psychosis (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs) are associated with acute angle-closure glaucoma (AACG) in case reports and a case-controlled study. AACG may cause symptoms including <b>eye pain</b>, changes in vision, swelling, and redness, which can rapidly lead to permanent blindness if not treated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27993931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27993931'])">Ref</a></span>). In addition, SSRIs may be associated with <b>mydriasis</b> and an increased risk of cataract development (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28342338','lexi-content-ref-24631758','lexi-content-ref-20443647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28342338','lexi-content-ref-24631758','lexi-content-ref-20443647'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> AACG: Unclear; hypothesized SSRIs may increase the intraocular pressure via serotonergic effects on ciliary body muscle activation and pupil dilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27135704','lexi-content-ref-27993931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27135704','lexi-content-ref-27993931'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">For AACG:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>≥50 years of age (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Hyperopia (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Personal or family history of AACG (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851','lexi-content-ref-11793621']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851','lexi-content-ref-11793621'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Inuit or Asian descent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Serotonin syndrome</b> has been reported and typically occurs with coadministration of multiple medications that increase synaptic serotonin, but may also occur with a single agent at therapeutic doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8628448','lexi-content-ref-9088888','lexi-content-ref-34381508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8628448','lexi-content-ref-9088888','lexi-content-ref-34381508'])">Ref</a></span>). Serotonin syndrome may result in a spectrum of symptoms, such as anxiety, agitation, confusion, delirium, hyperreflexia, muscle rigidity, myoclonus, tachycardia, tachypnea, and tremor. Severe cases may cause hyperthermia, significant autonomic instability (ie, rapid and severe changes in blood pressure and pulse), coma, and seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; overstimulation of serotonin receptors by medications that increase synaptic serotonin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; in the majority of cases (74%), onset occurred within 24 hours of treatment initiation, overdose, or change in dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10941349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10941349'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of drugs that increase serotonin synthesis, block serotonin reuptake and/or impair serotonin metabolism (eg, monamine oxidase inhibitors [MAOIs]). Of note, concomitant use of some serotonergic agents, such as MAOIs, are contraindicated.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sexual dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs) are commonly associated with <b>sexual disorder</b> in both men and women. The following adverse reactions have been associated with SSRI use: <b>Ejaculatory disorder</b>, orgasm disturbance, <b>anorgasmia,</b>
<b>erectile dysfunction</b>, decreased libido, and loss of libido (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9805292','lexi-content-ref-7949503','lexi-content-ref-29955469','lexi-content-ref-11229449','lexi-content-ref-9292833','lexi-content-ref-36445984','lexi-content-ref-19440080','lexi-content-ref-26003261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9805292','lexi-content-ref-7949503','lexi-content-ref-29955469','lexi-content-ref-11229449','lexi-content-ref-9292833','lexi-content-ref-36445984','lexi-content-ref-19440080','lexi-content-ref-26003261'])">Ref</a></span>). Priapism and decreased genital sensation have also been reported with SSRIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18173768','lexi-content-ref-26003261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18173768','lexi-content-ref-26003261'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Increases in serotonin may affect other hormones and neurotransmitters involved in sexual function; in particular, testosterone's effect on sexual arousal and dopamine's role in achieving orgasm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955469','lexi-content-ref-10333979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955469','lexi-content-ref-10333979'])">Ref</a></span>). Elevated serotonin levels may also decrease nitrous oxide levels (due to inhibition of nitrous oxide synthase), resulting in impaired penile blood vessel relaxation and erectile dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36445984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36445984'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; one study observed an onset of sexual dysfunction within the first 2 to 4 weeks of treatment with fluvoxamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10192595']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10192595'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Depression (sexual dysfunction is commonly associated with depression; SSRI-associated sexual dysfunction may be difficult to differentiate in treated patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12243609']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12243609'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal thinking and behavior</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants are associated with an increased risk of <b>suicidal ideation</b> and <b>suicidal tendencies</b> in pediatric and young adult patients (18 to 24 years of age) in short-term studies. In adults ≥24 years of age, short-term studies did not show an increased risk of suicidal thinking and behavior, and in older adults (≥65 years of age) a decreased risk was observed. Although data have yielded inconsistent results regarding the association of antidepressants and risk of suicide, particularly among adults, collective evidence shows a trend of an elevated risk of suicidality in younger age groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231'])">Ref</a></span>). Of note, the risk of a suicide attempt is inherent in major depression and may persist until remission occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not established; one of several postulated mechanisms is antidepressants may energize suicidal patients to act on impulses; another suggests that antidepressants may transiently worsen depressive symptoms leading to the emergence of suicidal thoughts and actions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; increased risk observed in short-term studies (ie, &lt;4 months) in pediatric and young adults; it is unknown whether this risk extends to long-term use (ie, &gt;4 months).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depression (risk of suicide is associated with major depression and may persist until remission occurs)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Withdrawal syndrome</b>, consisting of both somatic symptoms (eg, dizziness, chills, light-headedness, vertigo, shock-like sensations, paresthesia, fatigue, headache, nausea, tremor, diarrhea, visual disturbances) and psychological symptoms (eg, anxiety, agitation, confusion, insomnia, irritability, mania), have been reported in adult and pediatric patients, primarily following abrupt discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Diler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Diler.1'])">Ref</a></span>). Withdrawal symptoms may also occur following gradual tapering (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9549249','lexi-content-ref-8486592','lexi-content-ref-25721705','lexi-content-ref-15906018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9549249','lexi-content-ref-8486592','lexi-content-ref-25721705','lexi-content-ref-15906018'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Withdrawal; due to reduced availability of serotonin in the CNS with decreasing levels of the selective serotonin reuptake inhibitor. Other neurotransmission systems, including increased glutamine and dopamine, may also be affected as well as the hypothalamic-pituitary-adrenal axis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30501420','lexi-content-ref-23596418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30501420','lexi-content-ref-23596418'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; expected onset is 1 to 10 days (following either abrupt or tapered discontinuation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25721705','lexi-content-ref-30501420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25721705','lexi-content-ref-30501420'])">Ref</a></span>); in one study, withdrawal symptoms were most frequently reported on day 5 following fluvoxamine discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8486592']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8486592'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt discontinuation (rather than gradual dosage reduction) of an antidepressant treatment that has lasted &gt;3 weeks, particularly a drug with a half-life &lt;24 hours (eg, paroxetine, venlafaxine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-25677972'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of antidepressant withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23459282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23459282'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23459282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23459282'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F173568"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults, adolescents, and children. Frequency varies by dosage form (extended release and immediate release) and indication. Adverse reactions reported as a composite of all indications including off-label uses.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (6% to 13%), diarrhea (11% to 18%), nausea (34% to 40%), xerostomia (10% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (14% to 26%), dizziness (11% to 12%), drowsiness (22% to 27%; literature suggests incidence occurs more frequently in adults compared to children and adolescents [Safer 2006]), headache (22% to 32%), insomnia (21% to 35%), nervousness (12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (≥1%), hypertension (2%), hypotension (≥1%), palpitations (3%), syncope, vasodilation (3%; including feeling hot and flushing sensation)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (2%), diaphoresis (7%), ecchymoses (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (2% to 10%; incidence higher in males), heavy menstrual bleeding (3%), weight gain (≥1%), weight loss (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (4% to 10%), dental caries (2% to 3%; including tooth abscess, toothache, and tooth loss), dysgeusia (2% to 3%), dyspepsia (8% to 10%), dysphagia (2%), flatulence (4%), gingivitis (2%), vomiting (5% to 6%; literature suggests prevalence is higher in adolescents compared to adults and is two- to threefold more prevalent in children compared to adults [Safer 2006])</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anorgasmia (2% to 5%)<span class="lexi-table-link-container"> (<a aria-label="Anorgasmia table link" class="lexi-table-link" data-table-id="lexi-content-anorgasmia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anorgasmia')">table 1</a>)</span><span class="table-link" style="display:none;">Anorgasmia</span>, ejaculatory disorder (8% to 10%; including delayed ejaculation and ejaculation failure)<span class="lexi-table-link-container"> (<a aria-label="Ejaculatory Disorder table link" class="lexi-table-link" data-table-id="lexi-content-ejaculatory-disorder" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ejaculatory-disorder')">table 2</a>)</span><span class="table-link" style="display:none;">Ejaculatory Disorder</span>, erectile dysfunction (2%)<span class="lexi-table-link-container"> (<a aria-label="Erectile Dysfunction table link" class="lexi-table-link" data-table-id="lexi-content-erectile-dysfunction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-erectile-dysfunction')">table 3</a>)</span><span class="table-link" style="display:none;">Erectile Dysfunction</span>, polyuria (2%), sexual disorder (2% to 4%), urinary frequency (3%), urinary retention (1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anorgasmia" frame="border" id="lexi-content-anorgasmia" rules="all">
<caption style="text-align:center;">
<b>Fluvoxamine: Adverse Reaction: Anorgasmia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fluvoxamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fluvoxamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obsessive compulsive disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">124</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">124</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obsessive compulsive disorder or depression</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">892</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">778</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ejaculatory Disorder" frame="border" id="lexi-content-ejaculatory-disorder" rules="all">
<caption style="text-align:center;">
<b>Fluvoxamine: Adverse Reaction: Ejaculatory Disorder</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fluvoxamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fluvoxamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obsessive compulsive disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obsessive compulsive disorder or depression</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Erectile Dysfunction" frame="border" id="lexi-content-erectile-dysfunction" rules="all">
<caption style="text-align:center;">
<b>Fluvoxamine: Adverse Reaction: Erectile Dysfunction</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fluvoxamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fluvoxamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obsessive compulsive disorder or depression</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Infection: Viral infection (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (2%), amnesia (≥1%), anxiety (5% to 6%), apathy (3%), central nervous system stimulation (2%; including activation syndrome), changes in thinking (3%), chills (2%), depression (2%), hypertonia (2%), malaise, manic reaction (≥1%), myoclonus (≥1%), neurosis (2%), pain (10%), psychotic reaction (≥1%), tremor (5% to 6%), twitching (2%), yawning (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hyperkinetic muscle activity (≥1%), hypokinesia (≥1%), myalgia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia (2% to 3%; including blurred vision)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (2%), epistaxis (2%)<span class="lexi-table-link-container"> (<a aria-label="Epistaxis table link" class="lexi-table-link" data-table-id="lexi-content-epistaxis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-epistaxis')">table 4</a>)</span><span class="table-link" style="display:none;">Epistaxis</span>, flu-like symptoms (3%), increased cough (≥1%), laryngitis (3%), pharyngitis (6%), sinusitis (≥1%), upper respiratory tract infection (9%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Epistaxis" frame="border" id="lexi-content-epistaxis" rules="all">
<caption style="text-align:center;">
<b>Fluvoxamine: Adverse Reaction: Epistaxis</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fluvoxamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fluvoxamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Obsessive compulsive disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">124</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">124</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, angina pectoris, atrioventricular block, bradycardia, cardiac conduction delay, cardiac fibrillation, cardiomyopathy, cold extremity, embolism, irregular pulse, pericarditis, phlebitis, ST segment changes on ECG, supraventricular extrasystole</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, eczema, exfoliative dermatitis, furunculosis, pallor, seborrhea, skin discoloration, skin photosensitivity, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration, diabetes mellitus, goiter, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypoglycemia, hypokalemia, hypothyroidism, increased lactate dehydrogenase, increased libido, menopause, premenstrual syndrome, suppressed menstruation</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia, biliary colic, cholecystitis, cholelithiasis, colitis, eructation, esophagitis, fecal incontinence, gastritis, gastrointestinal hemorrhage, gastrointestinal ulcer, glossitis, hematemesis, hemorrhoids, hiccups, intestinal obstruction, melena, rectal hemorrhage, sialorrhea, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abnormal uterine bleeding, anuria, cystitis, dysuria, hematuria, hemospermia, lactation, nocturia, oliguria, urination disorder (impaired urination), vaginal hemorrhage, vaginitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, leukocytosis, leukopenia, lymphadenopathy, purpuric disease, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, agoraphobia, akathisia, akinesia, altered sense of smell, ataxia, central nervous system depression, cerebrovascular accident, coma, confusion, delirium, depersonalization, emotional lability, euphoria, extrapyramidal reaction, hallucination, hemiplegia, hostility, hypersomnia, hypochondriasis, hyporeflexia, hypotonia, hysteria, mutism, myasthenia, paralysis, paranoid ideation, phobia, psychosis, seizure, sleep disorder, slurred speech, stupor, suicidal tendencies (including suicidal ideation), trismus, unsteady gait, vertigo, withdrawal syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, arthritis, bursitis, dyskinesia, dystonia, muscle spasm, myopathy, neck pain, neck stiffness, tardive dyskinesia, torticollis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance, conjunctivitis, corneal ulcer, diplopia, dry eye syndrome, eye pain, mydriasis, visual field defect</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrolithiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, asthma, hemoptysis, hoarseness, hyperventilation, laryngismus, obstructive pulmonary disease, pneumonia, pulmonary infarct, respiratory congestion (upper airway)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Genitourinary: Priapism</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolonged QT interval on ECG, Raynaud disease (Khouri 2016; Peiró 2007), shock, tachycardia, vasculitis, ventricular arrhythmia, ventricular tachycardia (including torsades de pointes)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous skin disease, Stevens-Johnson syndrome, toxic epidermal necrolysis (Wolkenstein 1993)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea, hyponatremia (Gabriel 2009), porphyria, SIADH (Arinzon 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Bruxism, gastroesophageal reflux disease, glossalgia, pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, decreased white blood cell count, Henoch-Schonlein purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait, aggressive behavior, dysarthria, fatigue, hyperactive behavior (including agitation, hyperactivation, hyperkinesis, and restlessness occurring in children at a two- to threefold higher incidence compared to adolescents; it is more prevalent in adolescents compared to adults) (Safer 2006), homicidal ideation, hypomania (Rihmer 1996), impulsivity, intoxicated feeling, irritability, jitteriness, lethargy, loss of consciousness, neuroleptic malignant syndrome (Stevens 2008), outbursts of anger, parkinsonism, serotonin syndrome (Bastani 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rhabdomyolysis (Zhang 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, kidney impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial lung disease</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Crying, fever</p></div>
<div class="block coi drugH1Div" id="F173583"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concurrent use with alosetron, pimozide, thioridazine, or tizanidine; use of monoamine oxidase inhibitors (MAOIs) intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either fluvoxamine or the MAO inhibitor); initiation of fluvoxamine in a patient receiving IV methylene blue.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Although fluvoxamine is contraindicated per the manufacturer labeling when used in combination with linezolid, new evidence suggests that the combination is unlikely to cause serotonin syndrome (0.06% to 3% risk), and therefore these agents can be administered concomitantly when necessary. Monitor patients on this combination; average duration of serotonin toxicity is ~4 days; however, risks may be greater with longer durations of concurrent therapy. Educate patients on the signs and symptoms of serotonin syndrome (Bai 2022; Butterfield 2012; Karkow 2017; Kufel 2023; Narita 2007; Taylor 2006a).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to fluvoxamine or any component of the formulation; concurrent use with astemizole, cisapride, mesoridazine, ramelteon, or terfenadine.</p></div>
<div class="block war drugH1Div" id="F173565"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: Has a low potential to impair cognitive or motor performance; caution operating hazardous machinery or driving.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease; fluvoxamine has not been systemically evaluated in patients with a recent history of MI or unstable heart disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; clearance is decreased and half-life and plasma concentrations are increased; a lower dosage may be needed. However, selective serotonin reuptake inhibitors such as fluvoxamine are considered the safest antidepressants to use in chronic liver disease because of their relative lack of side effects and high therapeutic index (Mullish 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a previous seizure disorder and avoid use with unstable seizure disorder. Discontinue use if seizures occur or if seizure frequency increases.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Smokers: Fluvoxamine levels may be lower in patients who smoke.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878466"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Due to limited long-term studies, the clinical usefulness of fluvoxamine should be periodically reevaluated in patients receiving the drug for extended intervals; effects of long-term use of fluvoxamine on pediatric growth, development, and maturation have not been directly assessed.</p></div>
<div class="block foc drugH1Div" id="F173577"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as maleate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 150 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as maleate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg</p></div>
<div class="block geq drugH1Div" id="F173561"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F2524580"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (fluvoxaMINE Maleate ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $10.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $10.93</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (fluvoxaMINE Maleate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $2.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $2.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $2.63 - $2.64</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866961"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as maleate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Luvox: 50 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg</p></div>
<div class="block admp drugH1Div" id="F52612880"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to meals. Do not chew or crush extended-release capsule; swallow whole.</p></div>
<div class="block adm drugH1Div" id="F6195124"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May be administered with or without food. Do not crush, open, or chew ER capsules.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Capsule, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER capsule cannot be opened. Consider switching to IR formulation, but dose adjustment may be necessary since the bioavailability of the IR formulation differs from the ER formulation.</p></div>
<div class="block sts drugH1Div" id="F173595"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Protect from high humidity and store at controlled room temperature 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and  86°F).</p></div>
<div class="block meg drugH1Div" id="F7874605"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Luvox CR capsule: <a href="/external-redirect?target_url=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F022033s011lbl.pdf%23page%3D26&amp;token=zn6tFcWX3d1LKVneWGtHYetYiD7LwOfcHSKNGmBS64BBkEtTNuIcbYAnyP%2FZnjt%2B%2BvOQfsjyozIeXi4xyVLyEVtuesHLPoguC5QlnJ6mYPfzZ3ss%2BA1DiFgf0ryXbyvI&amp;TOPIC_ID=13025" target="_blank">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022033s011lbl.pdf#page=26</a></p>
<p style="text-indent:-2em;margin-left:4em;">Fluvoxamine tablet: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021519s026lbl.pdf%23page%3D32&amp;token=FlXgzJdIWhkh9CSkzEpuCk8qnVEreLU9ugoS9ClPKX%2BrZijWi0kSv8IZE7G7mr9dB1vWAhjp1nh%2BYYGf5Sp2LhmMCwYCzkzM0sCfxWCQxahcTXAABMaoQJbyp%2F60P7P9&amp;TOPIC_ID=13025" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021519s026lbl.pdf#page=32</a></p></div>
<div class="block usep drugH1Div" id="F53566983"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of obsessive-compulsive disorder (OCD) (Immediate release: FDA approved in ages ≥8 years and adults; extended release: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F173650"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">FluvoxaMINE may be confused with flavoxATE, FLUoxetine, fluPHENAZine</p>
<p style="text-indent:-2em;margin-left:4em;">Luvox may be confused with Lasix, Levoxyl, Lovenox</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Selective Serotonin Reuptake Inhibitors (SSRIs) are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F173633"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2D6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (strong), CYP2C19 (moderate), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F173570"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Abrocitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acenocoumarol: FluvoxaMINE may increase the serum concentration of Acenocoumarol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agomelatine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Agomelatine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Almotriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: FluvoxaMINE may decrease the metabolism of Alosetron. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust doses as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: CYP1A2 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Anagrelide. CYP1A2 Inhibitors (Strong) may increase the serum concentration of Anagrelide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiplatelet Agents (P2Y12 Inhibitors): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: Serotonergic Agents (High Risk) may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Asenapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Astemizole: FluvoxaMINE may increase the serum concentration of Astemizole.  Management: Avoid this combination when possible. The combination is specifically contraindicated in at least some non-US labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belzutifan: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Belzutifan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.  Management: Consider alternatives to strong CYP1A2 inhibitors during therapy with bendamustine due to the potential for increased bendamustine plasma concentrations and increased bendamustine toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: Selective Serotonin Reuptake Inhibitors may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivaracetam: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Brivaracetam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromazepam: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bromazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the adverse/toxic effect of FluvoxaMINE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caffeine and Caffeine Containing Products: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Caffeine and Caffeine Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carisoprodol: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Carisoprodol. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Carisoprodol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilostazol: CYP2C19 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Cilostazol. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.  Management: Reduce the cilostazol dose to 50 mg twice daily in patients who are also receiving moderate inhibitors of CYP2C19. Monitor clinical response to cilostazol closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cisapride: FluvoxaMINE may increase the serum concentration of Cisapride.  Management: Avoid this combination when possible. The combination is specifically contraindicated in at least some non-US labeling.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: May enhance the antiplatelet effect of FluvoxaMINE. Citalopram may enhance the serotonergic effect of FluvoxaMINE. This could result in serotonin syndrome. FluvoxaMINE may increase the serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day. Monitor for signs and symptoms of bleeding, QTc prolongation, or serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor) if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: CYP2C19 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of CloBAZam. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of CloBAZam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of CloZAPine.  Management: Reduce the dose of clozapine to one-third of the original dose when adding a strong CYP1A2 inhibitor and monitor patient response closely. Return to the original clozapine dose when the strong CYP1A2 inhibitor is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyclobenzaprine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of FluvoxaMINE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexlansoprazole: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Dexlansoprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate-Methylphenidate: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: May enhance the antiplatelet effect of FluvoxaMINE. DULoxetine may enhance the serotonergic effect of FluvoxaMINE. This could result in serotonin syndrome. FluvoxaMINE may increase the serum concentration of DULoxetine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: FluvoxaMINE may increase the serum concentration of Erlotinib.  Management: Avoid use of this combination when possible.  When the combination must be used, monitor the patient closely for the development of severe adverse reactions, and if such severe reactions occur, reduce the erlotinib dose (in 50 mg decrements).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etizolam: FluvoxaMINE may increase the serum concentration of Etizolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Fenfluramine.  Management: Limit fenfluramine dose to 20 mg/day without concurrent stiripentol or to 17 mg/day with concomitant stiripentol and clobazam when used with a strong CYP1A2 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Avoid use of this combination if possible. If the combination cannot be avoided, monitor closely for evidence of reduced response to the selective serotonin reuptake inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of FluvoxaMINE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: FluvoxaMINE may increase the serum concentration of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lansoprazole: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Lansoprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levobupivacaine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: May enhance the serotonergic effect of FluvoxaMINE. This could result in serotonin syndrome. FluvoxaMINE may increase the serum concentration of Levomethadone. Management: Monitor for increased methadone effects/toxicities if combined with fluvoxamine. Also monitor for signs and symptoms of serotonin syndrome/serotonin toxicity if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP1A2 Inhibitors (Strong) may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib.  Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: FluvoxaMINE may increase the serum concentration of Lumateperone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Melatonin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May enhance the serotonergic effect of FluvoxaMINE. This could result in serotonin syndrome. FluvoxaMINE may increase the serum concentration of Methadone. Management: Monitor for increased methadone effects/toxicities if combined with fluvoxamine. Also monitor for signs and symptoms of serotonin syndrome/serotonin toxicity if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methysergide: FluvoxaMINE may increase the serum concentration of Methysergide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Consider monitoring for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mexiletine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Mexiletine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Antidepressant). This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of OLANZapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omeprazole: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Omeprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists (metabolized by CYP3A4 and CYP2D6): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists (metabolized by CYP3A4): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the adverse/toxic effect of Serotonergic Agents (High Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pentoxifylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.  Management: Avoid concomitant use of pirfenidone and strong CYP1A2 inhibitors whenever possible. If combined, decrease the pirfenidone dose to 801 mg per day (267 mg three times daily) and monitor for increased pirfenidone toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomalidomide: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.  Management: Avoid when possible. If coadministration is necessary, reduce the pomalidomide dose to 2 mg and monitor for increased pomalidomide effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Proguanil: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Proguanil. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Proguanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Propranolol.  Management: Use a lower initial propranolol dose and be more cautious during propranolol dose titration when combined with strong CYP1A2 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: FluvoxaMINE may increase the serum concentration of QuiNIDine. QuiNIDine may increase the serum concentration of FluvoxaMINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramelteon: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Ramelteon. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: May enhance the serotonergic effect of FluvoxaMINE. This could result in serotonin syndrome. FluvoxaMINE may increase the serum concentration of Ramosetron. Management: Monitor for increased ramosetron effects/toxicities, including signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability) when these drugs are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rasagiline: FluvoxaMINE may enhance the serotonergic effect of Rasagiline. This could result in serotonin syndrome. FluvoxaMINE may increase the serum concentration of Rasagiline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riluzole: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Riluzole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast-Containing Products: FluvoxaMINE may increase serum concentrations of the active metabolite(s) of Roflumilast-Containing Products. FluvoxaMINE may increase the serum concentration of Roflumilast-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CYP1A2 Inhibitors (Strong) may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPivacaine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of ROPivacaine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Safinamide: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Use the lowest effective dose of SSRIs in patients treated with safinamide and monitor for signs and symptoms of serotonin syndrome/serotonin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of other Selective Serotonin Reuptake Inhibitors. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of other Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selegiline: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Selegiline. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk, Miscellaneous): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Non-Opioid CNS Depressants: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Opioids (High Risk): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Serotonin/Norepinephrine Reuptake Inhibitors. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Weak) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: May increase the serum concentration of FluvoxaMINE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Tasimelteon. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terfenadine: FluvoxaMINE may increase the serum concentration of Terfenadine.  Management: Avoid this combination when possible. The combination is specifically contraindicated in at least some non-US labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Theophylline Derivatives.  Management: Consider avoidance of this combination. If coadministration is necessary, consider an empiric theophylline dose reduction to one-third of the original theophylline dose. Monitor for increased theophylline serum concentrations and toxicities when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Selective Serotonin Reuptake Inhibitors may enhance the hyponatremic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: FluvoxaMINE may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of TiZANidine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of FluvoxaMINE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TOLBUTamide: CYP2C9 Inhibitors (Weak) may increase the serum concentration of TOLBUTamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk for serotonin syndrome/serotonin toxicity and seizures may be increased. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and seizures when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: FluvoxaMINE may enhance the serotonergic effect of Tricyclic Antidepressants. FluvoxaMINE may increase the serum concentration of Tricyclic Antidepressants.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations/effects if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: FluvoxaMINE may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and consider avoiding a second dose for 24 hours when used with fluvoxamine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Drugs Suspected of Causing SIADH may enhance the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venlafaxine: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Venlafaxine. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Venlafaxine. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Voriconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors. Vortioxetine may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: FluvoxaMINE may enhance the CNS depressant effect of Zolpidem. FluvoxaMINE may increase the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54008900"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Fluvoxamine is approved for the treatment of obsessive-compulsive disorder (OCD) and used off label for the treatment of unipolar major depressive disorder (WFSBP [Bauer 2013]). If treatment for OCD or major depressive disorder is initiated for the first time in patients planning to become pregnant, agents other than fluvoxamine are preferred (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Selective serotonin reuptake inhibitors (SSRIs) may be associated with male and female treatment-emergent sexual dysfunction (Coskuner 2018; WFSBP [Bauer 2013]). Decreased libido has been reported in males and females; abnormal/delayed ejaculation and impotence have been reported in males with fluvoxamine use. This may also be a manifestation of the psychiatric disorder. The actual risk associated with fluvoxamine is not known. SSRI-related sexual dysfunction may resolve with dose reduction or discontinuation of the SSRI; in some cases, sexual dysfunction may persist once therapy is discontinued (Coskuner 2018; Jing 2016; Waldinger 2015).</p></div>
<div class="block pri drugH1Div" id="F173585"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Fluvoxamine crosses the human placenta (Newport 2003).</p>
<p style="text-indent:0em;margin-top:2em;">As a class, selective serotonin reuptake inhibitors (SSRIs) have been evaluated extensively in pregnant patients. Studies focusing on newborn outcomes following first trimester exposure often have inconsistent results due to differences in study design and confounders such as maternal disease and social factors (Anderson 2020; Biffi 2020; Fitton 2020; Reefhuis 2015; Womersley 2017). Adverse effects in the newborn following SSRI exposure late in the third trimester can include apnea, constant crying, cyanosis, feeding difficulty, hyperreflexia, hypo- or hypertonia, hypoglycemia, irritability, jitteriness, respiratory distress, seizures, temperature instability, tremor, and vomiting. Prolonged hospitalization, respiratory support, or tube feedings may be required. Symptoms may be due to the toxicity of the SSRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn has been reported with SSRI exposure; although the absolute risk is small, monitoring of infants exposed to SSRIs late in pregnancy is recommended (Masarwa 2019; Ng 2019). The long-term effects of in utero SSRI exposure on infant neurodevelopment and behavior are not known (CANMAT [MacQueen 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of fluvoxamine may be altered. Based on limited data, maternal serum concentrations may be decreased in the third trimester. Close clinical monitoring as pregnancy progresses and therapeutic drug monitoring to detect patterns of changing plasma concentrations are recommended to assist dose adjustment when needed (Schoretsanitis 2020; Westin 2017).</p>
<p style="text-indent:0em;margin-top:2em;">If treatment for obsessive-compulsive disorder or major depressive disorder is initiated for the first time during pregnancy, fluvoxamine is not one of the preferred SSRIs (CANMAT [MacQueen 2016]; Larsen 2015). If pregnancy occurs during fluvoxamine treatment, changing to another SSRI can be considered if safe in relation to the patient's disease (Larsen 2015). Untreated or inadequately treated psychiatric illness may lead to poor adherence with prenatal care and adverse pregnancy outcomes. Therapy with antidepressants during pregnancy should be individualized; treatment with antidepressant medication is recommended for pregnant patients with severe major depressive disorder (ACOG 2008; CANMAT [MacQueen 2016]). Patients treated for major depression and who are euthymic prior to pregnancy are more likely to experience a relapse when medication is discontinued (68%) as compared to pregnant patients who continue taking antidepressant medications (26%) (Cohen 2006).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to antidepressant medications is ongoing. Patients exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants. Pregnant patients 18 to 45 years of age or their health care providers may contact the registry to enroll; enrollment should be done as early in pregnancy as possible (1-866-961-2388 or https://womensmentalhealth.org/research/pregnancyregistry/antidepressants/).</p></div>
<div class="block mopp drugH1Div" id="F53566982"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Evaluate mental status, suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks, or other unusual changes in behavior; signs/symptoms of serotonin syndrome; akathisia; weight and BMI (particularly in pediatric patients); hepatic function (baseline and as clinically indicated).</p></div>
<div class="block pha drugH1Div" id="F173564"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits CNS neuron serotonin uptake; minimal or no effect on reuptake of norepinephrine or dopamine; does not significantly bind to alpha-adrenergic, histamine or cholinergic receptors</p></div>
<div class="block phk drugH1Div" id="F173582"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Anxiety disorders (obsessive-compulsive, panic, and posttraumatic stress disorder): Initial effects may be observed within 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Issari 2016; Varigonda 2016; WFSBP [Bandelow 2023a]); some experts suggest up to 12 weeks of treatment may be necessary for response, particularly in patients with obsessive-compulsive disorder and posttraumatic stress disorder (BAP [Baldwin 2014]; Katzman 2014; WFSBP [Bandelow 2023a]; WFSBP [Bandelow 2023b]).</p>
<p style="text-indent:-2em;margin-left:4em;">Depression: Initial effects may be observed within 1 to 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Papakostas 2006; Posternak 2005; Szegedi 2009; Taylor 2006b).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~25 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~80%, primarily to albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via oxidative demethylation and deamination</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Immediate release: 53%; Extended release: 84%; not significantly affected by food.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~14 to 16 hours; ~17 to 26 hours in the elderly</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 3 to 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~85% as metabolites; ~2% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51192648"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: For the IR tablets, a 30% decrease in clearance has been observed in patients with hepatic impairment compared with healthy subjects. Half-life and AUC increased by ~50% following a single dose of immediate release fluvoxamine in patients with alcoholic liver cirrhosis (van Harten 1993).</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: For the immediate-release tablets, area under the curve (AUC) and C<sub>max</sub> were 1.5- and 2.7-fold higher, respectively, in children 6 to 11 years of age. Female children had significantly higher AUC and C<sub>max</sub> compared with males. AUC and C<sub>max</sub> in adolescents 12 to 17 years of age were similar to adults and there were no gender differences.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: For the immediate-release tablets, compared with younger subjects, clearance is reduced by 50% and mean max plasma concentrations are 40% higher in the elderly.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: For the extended-release capsules, the AUC and C<sub>max</sub> were increased by approximately 60% in healthy women compared with men.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F173586"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo fluvoxamine | Faverin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Luvox</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Felixsan | Floxyfral</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo fluvoxamine | Faverin | Fluvoxamine an | Fluvoxamine ga | Luvox | Movox | Voxam</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Relafin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Dumirox | Floxyfral | Fluvoxamine eg | Fluvoxamine sandoz | Fluvoxamine teva generics belgium</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Fevarin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Luvox | Revoc</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Flox-ex | Floxyfral bruchrille | Floxyfral m bruchrille | Floxyfral ohne bruchrill | Floxyfral ohne bruchrille</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Luvox</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Luvox</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Fluvoxamina maleato | Luvox</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Fevarin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Desifluvoxamin | Fevarin | Fluvohexal | Fluvoxadura | Fluvoxamin al | Fluvoxamin beta | Fluvoxamin Ratiopharm | Fluvoxamin stada | Fluvoxamin Synthon | Fluvoxamin Teva</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Fevarin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Faverin | Fluvoxamine | Fluxamine | Statomain</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Dumirox | Fluvoxamina Sandoz</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Fevarin | Fluvosol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Floxyfral | Fluvoxamine Actavis | Fluvoxamine eg | Fluvoxamine merck | Fluvoxamine sandoz | Fluvoxamine teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Faverin | Fluvoxamine | Fluvoxamine arrow | Fluvoxamine cox | Fluvoxamine kent</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dumyrox | Faverin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo fluvoxamine | Faverin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Fevarin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Fevarin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Luvox</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Faverin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Favoxil</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cererest | Fluoxa | Fluvaris | Fluvator | Fluvo | Fluvoxin | Frext | Ocdox | Ocivox | Oxvun | Psyvoxin | Revilife | Sorest | Uvamat | Uvox | Voxaday | Voxamin | Voxidep</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Dumirox | Fevarin | Fluvoxamina EG | Maveral</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Faverin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Depromel | Fluvoxamine maleate mylan | Fluvoxamine maleate np | Fluvoxamine maleate teva kowa | Luvox</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Faverin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dumirox | Luvox</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Apo fluvoxamine | Faverin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Faverin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Fevarin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Dumirox | Floxyfral</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Fevarin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Fluvoxamina synthon | Forezol | Luvox | Vuminix</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo fluvoxamine | Fluvox | Luvox</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fevarin | Fluvoxamine Maleaat EB | Fluvoxamine-Maleaat A | Fluvoxaminemaleaat | Fluvoxaminemaleaat CF | Fluvoxaminemaleaat Katwijk | Fluvoxaminemaleaat Merck | Fluvoxaminemaleaat PCH | Fluvoxaminemaleaat Sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fevarin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Fluvoxamine</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Luvox</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Faverin | Voxamine</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Amvoxa | Faverin | Fluvox | Fulvana | Oxamine | Revilife | Voxamine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Fevarin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dumyrox | Fluvoxamina Generis</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Luvox</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Faverin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Deprivox | Fevarin | Fluvoxamine teva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Fevarin | Rokona</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo fluvoxamine | Faverin | Fluvoxamine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fevarin | Fluvosol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Faverin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Avoxin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Fevarin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Faverin | Fluvoxin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Floxyfral</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Faverin | Fluvamteva | Revoxin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anwu | Fluvoxin | Lote | Luvox</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Fevarin | Fluvoxamine</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Faverin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dumirox | Fluvoprex</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Faverin | Fluvoxamine oethmaan | Luvox</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21961502">
<a name="21961502"></a>Aigner M, Treasure J, Kaye W, Kasper S; WFSBP Task Force on Eating Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. <i>World J Biol Psychiatry</i>. 2011;12(6):400-443.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/21961502/pubmed" id="21961502" target="_blank">21961502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22176943">
<a name="22176943"></a>American Academy of Child and Adolescent Psychiatry (AACAP). Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2012;51(1):98-113. doi:10.1016/j.jaac.2011.09.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/22176943/pubmed" id="22176943" target="_blank">22176943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation. <i>Obstet Gynecol.</i> 2008;111(4):1001-1020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2004">
<a name="APA.2004"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/acutestressdisorderptsd.pdf. Published November 2004. Accessed July 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.1">
<a name="APA.1"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Published October 2010. Accessed August 4, 2023. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2">
<a name="APA.2"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with obsessive-compulsive disorder. July 2007. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/ocd.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.3">
<a name="APA.3"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with panic disorder. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf. Published January 2009. Accessed March 11, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.4">
<a name="APA.4"></a>American Psychological Association (APA) Guideline Development Panel for the Treatment of Depressive Disorders. Clinical practice guideline for the treatment of depression across three age cohorts. Published February 16, 2019. https://www.apa.org/depression-guideline/guideline.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32777011">
<a name="32777011"></a>Anderson KN, Lind JN, Simeone RM, et al. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. <i>JAMA Psychiatry</i>. 2020;77(12):1246-1255. doi:10.1001/jamapsychiatry.2020.2453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/32777011/pubmed" id="32777011" target="_blank">32777011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21190637">
<a name="21190637"></a>Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. <i>J Clin Psychiatry</i>. 2010;71(12):1565-1575. doi:10.4088/JCP.09r05786blu<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/21190637/pubmed" id="21190637" target="_blank">21190637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777151">
<a name="24777151"></a>Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. <i>Am J Gastroenterol</i>. 2014;109(6):811-819. doi:10.1038/ajg.2014.82<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/24777151/pubmed" id="24777151" target="_blank">24777151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12086550">
<a name="12086550"></a>Arinzon ZH, Lehman YA, Fidelman ZG, Krasnyansky II. Delayed recurrent SIADH associated with SSRIs. <i>Ann Pharmacother</i>. 2002;36(7-8):1175-1177. doi:10.1345/aph.1A337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/12086550/pubmed" id="12086550" target="_blank">12086550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16573847">
<a name="16573847"></a>Asakura S; Tajima O; Koyama T. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. <i>Int J Neuropsychopharmacol</i>. 2007;10(2):263-274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/16573847/pubmed" id="16573847" target="_blank">16573847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11472786">
<a name="11472786"></a>Asnis GM, Hameedi FA, Goddard AW, et al. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. <i>Psychiatry Res</i>. 2001;103(1):1-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/11472786/pubmed" id="11472786" target="_blank">11472786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23699725">
<a name="23699725"></a>Auerbach AD, Vittinghoff E, Maselli J, Pekow PS, Young JQ, Lindenauer PK. Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery. <i>JAMA Intern Med</i>. 2013;173(12):1075-1081. doi:10.1001/jamainternmed.2013.714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/23699725/pubmed" id="23699725" target="_blank">23699725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36534400">
<a name="36534400"></a>Bai AD, McKenna S, Wise H, Loeb M, Gill SS. Association of linezolid with risk of serotonin syndrome in patients receiving antidepressants.<i> JAMA Netw Open</i>. 2022;5(12):e2247426. doi:10.1001/jamanetworkopen.2022.47426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/36534400/pubmed" id="36534400" target="_blank">36534400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36208621">
<a name="36208621"></a>Bakker S, Burggraaf JLI, Kruip MJHA, van der Meer FJM, Lijfering WM, van Rein N. Selective serotonin reuptake inhibitor use and risk of major bleeding during treatment with vitamin K antagonists: results of a cohort study. <i>Thromb Haemost</i>. 2023;123(2):245-254. doi:10.1055/a-1957-6305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/36208621/pubmed" id="36208621" target="_blank">36208621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23219059">
<a name="23219059"></a>Baldessarini RJ, Faedda GL, Offidani E, et al. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review. <i>J Affect Disord</i>. 2013;148(1):129-135. doi:10.1016/j.jad.2012.10.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/23219059/pubmed" id="23219059" target="_blank">23219059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24713617">
<a name="24713617"></a>Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. <i>J Psychopharmacol</i>. 2014;28(5):403-439. doi:10.1177/0269881114525674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/24713617/pubmed" id="24713617" target="_blank">24713617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9805292">
<a name="9805292"></a>Balon R. Fluvoxamine-induced erectile dysfunction responding to sildenafil. <i>J Sex Marital Ther</i>. 1998;24(4):313-317. doi:10.1080/00926239808403967<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/9805292/pubmed" id="9805292" target="_blank">9805292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900161">
<a name="35900161"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders. <i>World J Biol Psychiatry</i>. 2023a;24(2):79-117. doi:10.1080/15622975.2022.2086295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/35900161/pubmed" id="35900161" target="_blank">35900161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900217">
<a name="35900217"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part II: OCD and PTSD. <i>World J Biol Psychiatry</i>. 2023b;24(2):118-134. doi:10.1080/15622975.2022.2086296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/35900217/pubmed" id="35900217" target="_blank">35900217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28558366">
<a name="28558366"></a>Barbuti M, Pacchiarotti I, Vieta E, et al. Antidepressant-induced hypomania/mania in patients with major depression: evidence from the BRIDGE-II-MIX study. <i>J Affect Disord</i>. 2017;219:187-192. doi:10.1016/j.jad.2017.05.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/28558366/pubmed" id="28558366" target="_blank">28558366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28148614">
<a name="28148614"></a>Bartlett D. Drug-induced serotonin syndrome. <i>Crit Care Nurse</i>. 2017;37(1):49-54. doi:10.4037/ccn2017169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/28148614/pubmed" id="28148614" target="_blank">28148614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8628448">
<a name="8628448"></a>Bastani JB, Troester MM, Bastani AJ. Serotonin syndrome and fluvoxamine: a case study. <i>Nebr Med J</i>. 1996;81(4):107-109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/8628448/pubmed" id="8628448" target="_blank">8628448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879318">
<a name="23879318"></a>Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ; World Federation of Societies of Biological Psychiatry; Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/23879318/pubmed" id="23879318" target="_blank">23879318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25677972">
<a name="25677972"></a>Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. <i>World J Biol Psychiatry</i>. 2015;16(2):76-95. doi:10.3109/15622975.2014.1001786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/25677972/pubmed" id="25677972" target="_blank">25677972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12479080">
<a name="12479080"></a>Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. <i>World J Biol Psychiatry</i>. 2002;3(2):69-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/12479080/pubmed" id="12479080" target="_blank">12479080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Benedek.2009">
<a name="Benedek.2009"></a>Benedek DM, Friedman MJ, Zatzick D, Ursano RJ. Guideline watch (March 2009): Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/acutestressdisorderptsd-watch.pdf. Published March 2009. Accessed July 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9387089">
<a name="9387089"></a>Benazzi F. Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. <i>J Affect Disord</i>. 1997;46(1):73-77. doi:10.1016/s0165-0327(97)00082-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/9387089/pubmed" id="9387089" target="_blank">9387089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9549249">
<a name="9549249"></a>Benazzi F. SSRI discontinuation syndrome related to fluvoxamine. <i>J Psychiatry Neurosci</i>. 1998;23(2):94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/9549249/pubmed" id="9549249" target="_blank">9549249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22299006">
<a name="22299006"></a>Berle JO, Spigset O. Antidepressant use during breastfeeding. <i>Curr Womens Health Rev</i>. 2011;7(1):28-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/22299006/pubmed" id="22299006" target="_blank">22299006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32135392">
<a name="32135392"></a>Biffi A, Cantarutti A, Rea F, Locatelli A, Zanini R, Corrao G. Use of antidepressants during pregnancy and neonatal outcomes: an umbrella review of meta-analyses of observational studies. <i>J Psychiatr Res</i>. 2020;124:99-108. doi:10.1016/j.jpsychires.2020.02.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/32135392/pubmed" id="32135392" target="_blank">32135392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30081645">
<a name="30081645"></a>Bixby AL, VandenBerg A, Bostwick JR. Clinical management of bleeding risk with antidepressants. <i>Ann Pharmacother</i>. 2019;53(2):186-194. doi:10.1177/1060028018794005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/30081645/pubmed" id="30081645" target="_blank">30081645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8486592">
<a name="8486592"></a>Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. <i>J Clin Psychiatry</i>. 1993;54(4):146-149.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/8486592/pubmed" id="8486592" target="_blank">8486592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW, Shannon M. The serotonin syndrome. <i>N Engl J Med</i>. 2005;352(11):1112-1120. doi:10.1056/NEJMra041867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7477802">
<a name="7477802"></a>Brambilla F, Draisci A, Peirone A, Brunetta M. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in bulimia nervosa. <i>Neuropsychobiology.</i> 1995;32(2):68-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/7477802/pubmed" id="7477802" target="_blank">7477802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22139199">
<a name="22139199"></a>Butterfield JM, Lawrence KR, Reisman A, Huang DB, Thompson CA, Lodise TP. Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of phase III and IV randomized clinical trial data. <i>J Antimicrob Chemother</i>. 2012;67(2):494-502. doi:10.1093/jac/dkr467<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/22139199/pubmed" id="22139199" target="_blank">22139199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27508501">
<a name="27508501"></a>Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. <i>Psychother Psychosom</i>. 2016;85(5):270-288. doi:10.1159/000447034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/27508501/pubmed" id="27508501" target="_blank">27508501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20703452">
<a name="20703452"></a>Ceylan ME, Maner F. Long-term use of fluoxetine and multiple skeleton fractures. <i>Eur J Clin Pharmacol</i>. 2010;66(12):1279. doi:10.1007/s00228-010-0880-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/20703452/pubmed" id="20703452" target="_blank">20703452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27135704">
<a name="27135704"></a>Chen HY, Lin CL, Lai SW, Kao CH. Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma. <i>J Clin Psychiatry</i>. 2016;77(6):e692-e696. doi:10.4088/JCP.15m10038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/27135704/pubmed" id="27135704" target="_blank">27135704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23881712">
<a name="23881712"></a>Cheung AH, Kozloff N, Sacks D. Pediatric depression: an evidence-based update on treatment interventions. <i>Curr Psychiatry Rep</i>. 2013;15(8):381. doi:10.1007/s11920-013-0381-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/23881712/pubmed" id="23881712" target="_blank">23881712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29483201">
<a name="29483201"></a>Cheung AH, Zuckerbrot RA, Jensen PS, Laraque D, Stein REK; GLAD-PC Steering Group. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and ongoing management. <i>Pediatrics</i>. 2018;141(3):e20174082. doi:10.1542/peds.2017-4082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/29483201/pubmed" id="29483201" target="_blank">29483201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28342338">
<a name="28342338"></a>Chou PH, Chu CS, Chen YH, et al. Antidepressants and risk of cataract development: a population-based, nested case-control study. <i>J Affect Disord</i>. 2017;215:237-244. doi:10.1016/j.jad.2017.03.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/28342338/pubmed" id="28342338" target="_blank">28342338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16449615">
<a name="16449615"></a>Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. <i>JAMA</i>. 2006;295(5):499-507. doi:10.1001/jama.295.5.499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/16449615/pubmed" id="16449615" target="_blank">16449615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29463440">
<a name="29463440"></a>Coskuner ER, Culha MG, Ozkan B, Kaleagasi EO. Post-SSRI sexual dysfunction: preclinical to clinical. Is it fact or fiction?. <i>Sex Med Rev</i>. 2018;6(2):217-223. doi:10.1016/j.sxmr.2017.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/29463440/pubmed" id="29463440" target="_blank">29463440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19587851">
<a name="19587851"></a>Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. <i>Curr Neuropharmacol</i>. 2008;6(4):293-310. doi:10.2174/157015908787386104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/19587851/pubmed" id="19587851" target="_blank">19587851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craske.1">
<a name="Craske.1"></a>Craske M, Bystritsky A. Generalized anxiety disorder in adults: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 15, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Crone.2023">
<a name="Crone.2023"></a>Crone C, Fochtmann LJ, Attia E, et al; Guideline Writing Group<i>. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders</i>. 4th ed. American Psychiatric Association. Published 2023. Accessed March 15, 2023. doi:10.1176/appi.books.9780890424865</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18173768">
<a name="18173768"></a>Csoka AB, Bahrick A, Mehtonen OP. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. <i>J Sex Med</i>. 2008;5(1):227-233. doi:10.1111/j.1743-6109.2007.00630.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/18173768/pubmed" id="18173768" target="_blank">18173768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19716436">
<a name="19716436"></a>Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. <i>Clin Gastroenterol Hepatol</i>. 2009;7(12):1314-1321. doi:10.1016/j.cgh.2009.08.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/19716436/pubmed" id="19716436" target="_blank">19716436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15206657">
<a name="15206657"></a>Davidson J, Yaryura-Tobias J, DuPont R, et al. Fluvoxamine-Controlled Release Formulation for the Treatment of Generalized Social Anxiety Disorder. <i>J Clin Psychopharmacol</i>. 2004;24(2):118-125.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/15206657/pubmed" id="15206657" target="_blank">15206657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25262043">
<a name="25262043"></a>De Picker L, Van Den Eede F, Dumont G, Moorkens G, Sabbe BG. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. <i>Psychosomatics</i>. 2014;55(6):536-547. doi:10.1016/j.psym.2014.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/25262043/pubmed" id="25262043" target="_blank">25262043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1485372">
<a name="1485372"></a>De Vries MH, Raghoebar M, Mathlener IS, et al. Single and Multiple Oral Dose Fluvoxamine Kinetics in Young and Elderly Subjects. <i>Ther Drug Monit</i>. 1992;14(6):493-498.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/1485372/pubmed" id="1485372" target="_blank">1485372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diler.1">
<a name="Diler.1"></a>Diler R, Avci A. Selective Serotonin Reuptake Inhibitor Discontinuation Syndrome in Children: Six Case Reports. <i>Current Therapeutic Research</i>. 2002;63(3):188-197.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7949503">
<a name="7949503"></a>Dorevitch A, Davis H. Fluvoxamine-associated sexual dysfunction. <i>Ann Pharmacother</i>. 1994;28(7-8):872-874. doi:10.1177/106002809402800709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/7949503/pubmed" id="7949503" target="_blank">7949503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8305775">
<a name="8305775"></a>Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L. Fluvoxamine-associated manic behavior: a case series. <i>Ann Pharmacother</i>. 1993;27(12):1455-1457. doi:10.1177/106002809302701207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/8305775/pubmed" id="8305775" target="_blank">8305775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536379">
<a name="29536379"></a>Douros A, Ades M, Renoux C. Risk of intracranial hemorrhage associated with the use of antidepressants inhibiting serotonin reuptake: a systematic review. <i>CNS Drugs</i>. 2018;32(4):321-334. doi:10.1007/s40263-018-0507-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/29536379/pubmed" id="29536379" target="_blank">29536379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12925718">
<a name="12925718"></a>Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity. <i>QJM.</i> 2003;96(9):635-642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/12925718/pubmed" id="12925718" target="_blank">12925718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9088888">
<a name="9088888"></a>Ebert D, Albert R, May A, et al. The serotonin syndrome and psychosis-like side-effects of fluvoxamine clinical use--an estimation of incidence. <i>Eur Neuropsychopharmacol</i>. 1997;7(1):71-74. doi:10.1016/s0924-977x(96)00043-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/9088888/pubmed" id="9088888" target="_blank">9088888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24631758">
<a name="24631758"></a>Erie JC, Brue SM, Chamberlain AM, Hodge DO. Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study. <i>Am J Ophthalmol</i>. 2014;158(1):192-197.e1. doi:10.1016/j.ajo.2014.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/24631758/pubmed" id="24631758" target="_blank">24631758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25721705">
<a name="25721705"></a>Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. <i>Psychother Psychosom</i>. 2015;84(2):72-81. doi:10.1159/000370338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/25721705/pubmed" id="25721705" target="_blank">25721705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19621834">
<a name="19621834"></a>Fenske JN, Schwenk TL. Obsessive compulsive disorder: diagnosis and management. <i>Am Fam Physician</i>. 2009;80(3):239-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/19621834/pubmed" id="19621834" target="_blank">19621834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8834413">
<a name="8834413"></a>Fichter MM, Krüger R, Rief W, Holland R, Döhne J. Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology. <i>J Clin Psychopharmacol.</i> 1996;16(1):9-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/8834413/pubmed" id="8834413" target="_blank">8834413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9211569">
<a name="9211569"></a>Fichter MM, Leibl C, Krüger R, Rief W. Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa. <i>Pharmacopsychiatry.</i> 1997;30(3):85-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/9211569/pubmed" id="9211569" target="_blank">9211569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31648376">
<a name="31648376"></a>Fitton CA, Steiner MFC, Aucott L, et al. In utero exposure to antidepressant medication and neonatal and child outcomes: a systematic review. <i>Acta Psychiatr Scand</i>. 2020;141(1):21-33. doi:10.1111/acps.13120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/31648376/pubmed" id="31648376" target="_blank">31648376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11323729">
<a name="11323729"></a>Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. <i>N Engl J Med</i>. 2001;344(17):1279-1285.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/11323729/pubmed" id="11323729" target="_blank">11323729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluvoxamine.1">
<a name="Fluvoxamine.1"></a>Fluvoxamine Maleate extended-release capsules [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluvoxamine.2">
<a name="Fluvoxamine.2"></a>Fluvoxamine maleate extended-release capsules [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluvoxamine.3">
<a name="Fluvoxamine.3"></a>Fluvoxamine maleate tablets [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluvoxamine.4">
<a name="Fluvoxamine.4"></a>Fluvoxamine maleate tablets, USP [prescribing information]. Weston, FL: Apotex Corp; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11367967">
<a name="11367967"></a>Friedlander AH, Mahler ME. Major Depressive Disorder. Psychopathology, Medical Management, and Dental Implications. <i>J Am Dent Assoc</i>. 2001;132(5):629-638.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/11367967/pubmed" id="11367967" target="_blank">11367967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17485726">
<a name="17485726"></a>Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. <i>N Engl J Med</i>. 2007;356(23):2343-2346. doi:10.1056/NEJMp078015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/17485726/pubmed" id="17485726" target="_blank">17485726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19829765">
<a name="19829765"></a>Gabriel A. Serotonin reuptake inhibitor and fluvoxamine-induced severe hyponatremia in a 49-year-old man. <i>Case Rep Med</i>. 2009;2009:585193. doi:10.1155/2009/585193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/19829765/pubmed" id="19829765" target="_blank">19829765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9640489">
<a name="9640489"></a>Gerber PE, Lynd LD. Selective Serotonin Reuptake Inhibitor-induced Movement Disorders. <i>Ann Pharmacother</i>. 1998;32(6):692-698.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/9640489/pubmed" id="9640489" target="_blank">9640489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32215771">
<a name="32215771"></a>Gill N, Bayes A, Parker G. A review of antidepressant-associated hypomania in those diagnosed with unipolar depression-risk factors, conceptual models, and management. <i>Curr Psychiatry Rep</i>. 2020;22(4):20. doi:10.1007/s11920-020-01143-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/32215771/pubmed" id="32215771" target="_blank">32215771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12243609">
<a name="12243609"></a>Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. <i>Ann Pharmacother</i>. 2002;36(10):1577-1589. doi:10.1345/aph.1A195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/12243609/pubmed" id="12243609" target="_blank">12243609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1464219">
<a name="1464219"></a>Grimsley SR, Jann MW. Paroxetine, Sertraline, and Fluvoxamine: New Selective Serotonin Reuptake Inhibitors. <i>Clin Pharm</i>. 1992;11(11):930-957.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/1464219/pubmed" id="1464219" target="_blank">1464219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29522259">
<a name="29522259"></a>Grzeskowiak LE, Leggett C, Costi L, Roberts CT, Amir LH. Impact of serotonin reuptake inhibitor use on breast milk supply in mothers of preterm infants: a retrospective cohort study. <i>Br J Clin Pharmacol</i>. 2018;84(6):1373-1379. doi:10.1111/bcp.13575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/29522259/pubmed" id="29522259" target="_blank">29522259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11347722">
<a name="11347722"></a>Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/11347722/pubmed" id="11347722" target="_blank">11347722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17506225">
<a name="17506225"></a>Halperin D, Reber G. Influence of antidepressants on hemostasis. <i>Dialogues Clin Neurosci</i>. 2007;9(1):47-59. doi:10.31887/DCNS.2007.9.1/dhalperin<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/17506225/pubmed" id="17506225" target="_blank">17506225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16520440">
<a name="16520440"></a>Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. <i>Arch Gen Psychiatry</i>. 2006;63(3):332-339. doi:10.1001/archpsyc.63.3.332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/16520440/pubmed" id="16520440" target="_blank">16520440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29337001">
<a name="29337001"></a>Hathaway EE, Walkup JT, Strawn JR. Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders: How Long is Long Enough? <i>Curr Probl Pediatr Adolesc Health Care</i>. 2018;48(2):31-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/29337001/pubmed" id="29337001" target="_blank">29337001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28577352">
<a name="28577352"></a>Heller HM, Ravelli ACJ, Bruning AHL, et al. Increased postpartum haemorrhage, the possible relation with serotonergic and other psychopharmacological drugs: a matched cohort study. <i>BMC Pregnancy Childbirth</i>. 2017;17(1):166. doi:10.1186/s12884-017-1334-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/28577352/pubmed" id="28577352" target="_blank">28577352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23152227">
<a name="23152227"></a>Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. <i>Cochrane Database Syst Rev</i>. 2012;11(11):CD004851. doi:10.1002/14651858.CD004851.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/23152227/pubmed" id="23152227" target="_blank">23152227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2019">
<a name="Hirsch.2019"></a>Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 26, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.1">
<a name="Hirsch.1"></a>Hirsch M, Birnbaum RJ. Selective serotonin reuptake inhibitors: pharmacology, administration, and side effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9842788">
<a name="9842788"></a>Hudson JI, McElroy SL, Raymond NC, et al. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial.<i> Am J Psychiatry.</i> 1998;155(12):1756-1762. doi:10.1176/ajp.155.12.1756<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/9842788/pubmed" id="9842788" target="_blank">9842788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27249090">
<a name="27249090"></a>Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.<i> J Clin Psychiatry</i>. 2016;77(5):e605-e611. doi:10.4088/JCP.14r09758<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/27249090/pubmed" id="27249090" target="_blank">27249090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16896026">
<a name="16896026"></a>Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. <i>Ann Pharmacother</i>. 2006;40(9):1618-1622. doi:10.1345/aph.1G293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/16896026/pubmed" id="16896026" target="_blank">16896026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1770160">
<a name="1770160"></a>Jefferson JW, Greist JH, Perse TL, Rosenfeld R. Fluvoxamine-associated mania/hypomania in patients with obsessive-compulsive disorder. <i>J Clin Psychopharmacol</i>. 1991;11(6):391-392. doi:10.1097/00004714-199112000-00020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/1770160/pubmed" id="1770160" target="_blank">1770160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24314591">
<a name="24314591"></a>Jeong BO, Kim SW, Kim SY, Kim JM, Shin IS, Yoon JS. Use of serotonergic antidepressants and bleeding risk in patients undergoing surgery. <i>Psychosomatics</i>. 2014;55(3):213-220. doi:10.1016/j.psym.2013.08.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/24314591/pubmed" id="24314591" target="_blank">24314591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30501420">
<a name="30501420"></a>Jha MK, Rush AJ, Trivedi MH. When discontinuing SSRI antidepressants is a challenge: management tips. <i>Am J Psychiatry</i>. 2018;175(12):1176-1184. doi:10.1176/appi.ajp.2018.18060692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/30501420/pubmed" id="30501420" target="_blank">30501420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11793621">
<a name="11793621"></a>Jiménez-Jiménez FJ, Ortí-Pareja M, Zurdo JM. Aggravation of glaucoma with fluvoxamine. <i>Ann Pharmacother</i>. 2001;35(12):1565-1566. doi:10.1345/aph.1Z440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/11793621/pubmed" id="11793621" target="_blank">11793621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955469">
<a name="29955469"></a>Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: a narrative literature review. <i>Ment Health Clin</i>. 2016;6(4):191-196. doi:10.9740/mhc.2016.07.191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/29955469/pubmed" id="29955469" target="_blank">29955469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28796019">
<a name="28796019"></a>Karkow DC, Kauer JF, Ernst EJ. Incidence of serotonin syndrome with combined use of linezolid and serotonin reuptake inhibitors compared with linezolid monotherapy. <i>J Clin Psychopharmacol</i>. 2017;37(5):518-523. doi:10.1097/JCP.0000000000000751<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/28796019/pubmed" id="28796019" target="_blank">28796019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25081580">
<a name="25081580"></a>Katzman MA, Bleau P, Blier P, et al; Canadian Anxiety Guidelines Initiative Group. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i>. 2014;14(suppl 1):S1. doi: 10.1186/1471-244X-14-S1-S1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/25081580/pubmed" id="25081580" target="_blank">25081580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668373">
<a name="12668373"></a>Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. <i>Am J Psychiatry</i>. 2003;160(4):790-792. doi:10.1176/appi.ajp.160.4.790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/12668373/pubmed" id="12668373" target="_blank">12668373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30247774">
<a name="30247774"></a>Khanassov V, Hu J, Reeves D, van Marwijk H. Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: a systematic review and meta-analysis. <i>Int J Geriatr Psychiatry</i>. 2018;33(12):1688-1708. doi:10.1002/gps.4974<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/30247774/pubmed" id="30247774" target="_blank">30247774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26949933">
<a name="26949933"></a>Khouri C, Blaise S, Carpentier P, Villier C, Cracowski J, Roustit M. Drug-induced Raynaud's phenomenon: beyond beta-blockers. <i>Br J Clin Pharmacol</i>. 2016;82(1):6-16. doi:10.1111/bcp.12912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/26949933/pubmed" id="26949933" target="_blank">26949933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27993931">
<a name="27993931"></a>Kirkham J, Seitz D. Evidence of ocular side effects of SSRIs and new warnings. <i>Evid Based Ment Health</i>. 2017;20(1):27. doi:10.1136/eb-2016-102528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/27993931/pubmed" id="27993931" target="_blank">27993931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31447707">
<a name="31447707"></a>Kotapati VP, Khan AM, Dar S, et al. The effectiveness of selective serotonin reuptake inhibitors for treatment of obsessive-compulsive disorder in adolescents and children: a systematic review and meta-analysis. <i>Front Psychiatry</i>. 2019;10:523. doi:10.3389/fpsyt.2019.00523<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/31447707/pubmed" id="31447707" target="_blank">31447707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12033075">
<a name="12033075"></a>Kristensen JH, Hackett LP, Kohan R, Paech M, Ilett KF. The amount of fluvoxamine in milk is unlikely to be a cause of adverse effects in breastfed infants. <i>J Hum Lact</i>. 2002;18(2):139-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/12033075/pubmed" id="12033075" target="_blank">12033075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37160238">
<a name="37160238"></a>Kufel WD, Parsels KA, Blaine BE, Steele JM, Seabury RW, Asiago-Reddy EA. Real-world evaluation of linezolid-associated serotonin toxicity with and without concurrent serotonergic agents.<i> Int J Antimicrob Agents.</i> 2023;62(1):106843. doi:10.1016/j.ijantimicag.2023.106843<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/37160238/pubmed" id="37160238" target="_blank">37160238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21948719">
<a name="21948719"></a>Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. <i>CMAJ</i>. 2011;183(16):1835-1843. doi:10.1503/cmaj.100912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/21948719/pubmed" id="21948719" target="_blank">21948719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10755580">
<a name="10755580"></a>Lake MB, Birmaher B, Wassick S, et al. Bleeding and Selective Serotonin Reuptake Inhibitors in Childhood and Adolescence. <i>J Child Adolesc Psychopharmacol</i>. 2000;10(1):35-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/10755580/pubmed" id="10755580" target="_blank">10755580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18056231">
<a name="18056231"></a>Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. <i>Am J Psychiatry</i>. 2007;164(12):1786-1789. doi:10.1176/appi.ajp.2007.07050775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/18056231/pubmed" id="18056231" target="_blank">18056231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8946088">
<a name="8946088"></a>Leung M, Shore R. Fluvoxamine-associated bleeding. <i>Can J Psychiatry</i>. 1996;41(9):604-605. doi:10.1177/070674379604100919<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/8946088/pubmed" id="8946088" target="_blank">8946088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18188866">
<a name="18188866"></a>Lewis JD, Strom BL, Localio AR, et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. <i>Pharmacoepidemiol Drug Saf</i>. 2008;17(4):328-335. doi:10.1002/pds.1546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/18188866/pubmed" id="18188866" target="_blank">18188866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8804257">
<a name="8804257"></a>Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. <i>CMAJ</i>. 1996;155(5):519-527.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/8804257/pubmed" id="8804257" target="_blank">8804257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17919277">
<a name="17919277"></a>Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. <i>Aliment Pharmacol Ther</i>. 2008;27(1):31-40. doi:10.1111/j.1365-2036.2007.03541.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/17919277/pubmed" id="17919277" target="_blank">17919277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Luvox.1">
<a name="Luvox.1"></a>Luvox (fluvoxamine) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Luvox.2">
<a name="Luvox.2"></a>Luvox (fluvoxamine) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27486149">
<a name="27486149"></a>MacQueen GM, Frey BN, Ismail Z, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 6. Special populations: youth, women, and the elderly. <i>Can J Psychiatry</i>. 2016;61(9):588-603. doi:10.1177/0706743716659276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/27486149/pubmed" id="27486149" target="_blank">27486149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24094459">
<a name="24094459"></a>Mannesse CK, Jansen PA, Van Marum RJ, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. <i>Maturitas</i>. 2013;76(4):357-363. doi:10.1016/j.maturitas.2013.08.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/24094459/pubmed" id="24094459" target="_blank">24094459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19965920">
<a name="19965920"></a>Marshall AM, Nommsen-Rivers LA, Hernandez LL, et al. Serotonin Transport and Metabolism in the Mammary Gland Modulates Secretory Activation and Involution. <i>J Clin Endocrinol Metab</i>. 2010;95(2):837-846.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/19965920/pubmed" id="19965920" target="_blank">19965920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15289250">
<a name="15289250"></a>Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. <i>Arch Pediatr Adolesc Med</i>. 2004;158(8):773-780. doi:10.1001/archpedi.158.8.773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/15289250/pubmed" id="15289250" target="_blank">15289250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30170040">
<a name="30170040"></a>Masarwa R, Bar-Oz B, Gorelik E, Reif S, Perlman A, Matok I. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis. <i>Am J Obstet Gynecol</i>. 2019;220(1):57.e1-57.e13. doi:10.1016/j.ajog.2018.08.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/30170040/pubmed" id="30170040" target="_blank">30170040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10941349">
<a name="10941349"></a>Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. <i>Medicine (Baltimore)</i>. 2000;79(4):201-209. doi:10.1097/00005792-200007000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/10941349/pubmed" id="10941349" target="_blank">10941349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25248846">
<a name="25248846"></a>Mauri MC, Fiorentini A, Paletta S, Altamura AC. Pharmacokinetics of antidepressants in patients with hepatic impairment. <i>Clin Pharmacokinet</i>. 2014;53(12):1069-1081. doi:10.1007/s40262-014-0187-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/25248846/pubmed" id="25248846" target="_blank">25248846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16236688">
<a name="16236688"></a>Milano W, Siano C, Putrella C, Capasso A. Treatment of bulimia nervosa with fluvoxamine: a randomized controlled trial. <i>Adv Ther.</i> 2005;22(3):278-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/16236688/pubmed" id="16236688" target="_blank">16236688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11229449">
<a name="11229449"></a>Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. <i>J Clin Psychiatry</i>. 2001;62 suppl 3:10-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/11229449/pubmed" id="11229449" target="_blank">11229449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9292833">
<a name="9292833"></a>Montejo-González AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. <i>J Sex Marital Ther</i>. 1997;23(3):176-194. doi:10.1080/00926239708403923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/9292833/pubmed" id="9292833" target="_blank">9292833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36445984">
<a name="36445984"></a>Moses TEH, Javanbakht A. Resolution of selective serotonin reuptake inhibitor-associated sexual dysfunction after switching from fluvoxamine to fluoxetine. <i>J Clin Psychopharmacol</i>. 2023;43(1):71-73. doi:10.1097/JCP.0000000000001636<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/36445984/pubmed" id="36445984" target="_blank">36445984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14581256">
<a name="14581256"></a>Movig KL, Janssen MW, de Waal Malefijt J, Kabel PJ, Leufkens HG, Egberts AC. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. <i>Arch Intern Med</i>. 2003;163(19):2354-2358. doi:10.1001/archinte.163.19.2354<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/14581256/pubmed" id="14581256" target="_blank">14581256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30397569">
<a name="30397569"></a>Mullen S. Major depressive disorder in children and adolescents. <i>Ment Health Clin</i>. 2018;8(6):275-283. doi:10.9740/mhc.2018.11.275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/30397569/pubmed" id="30397569" target="_blank">30397569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25175904">
<a name="25175904"></a>Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. <i>Aliment Pharmacol Ther</i>. 2014;40(8):880-892. doi:10.1111/apt.12925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/25175904/pubmed" id="25175904" target="_blank">25175904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10192595">
<a name="10192595"></a>Nafziger AN, Bertino JS Jr, Goss-Bley AI, Kashuba AD. Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy. <i>J Clin Psychiatry</i>. 1999;60(3):187-190. doi:10.4088/jcp.v60n0307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/10192595/pubmed" id="10192595" target="_blank">10192595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17655517">
<a name="17655517"></a>Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. <i>Pharmacotherapy</i>. 2007;27(8):1189-1197. doi:10.1592/phco.27.8.1189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/17655517/pubmed" id="17655517" target="_blank">17655517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22132433">
<a name="22132433"></a>National Collaborating Centre for Mental Health (NCCMH). Depression: The Treatment and Management of Depression in Adults (Updated Edition). National Institute for Health &amp; Clinical Excellence (NICE). 2010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/22132433/pubmed" id="22132433" target="_blank">22132433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23624686">
<a name="23624686"></a>Nevatte T, O'Brien PM, Bäckström T, et al; Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. <i>Arch Womens Ment Health</i>. 2013;16(4):279-291. doi:10.1007/s00737-013-0346-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/23624686/pubmed" id="23624686" target="_blank">23624686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14566197">
<a name="14566197"></a>Newport DJ, Stowe ZN. Clinical management of perinatal depression: focus on paroxetine. <i>Psychopharmacol Bull.</i> 2003;37(suppl 1):148-166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/14566197/pubmed" id="14566197" target="_blank">14566197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30407100">
<a name="30407100"></a>Ng QX, Venkatanarayanan N, Ho CYX, Sim WS, Lim DY, Yeo WS. Selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn: an update meta-analysis. <i>J Womens Health (Larchmt)</i>. 2019;28(3):331-338. doi:10.1089/jwh.2018.7319<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/30407100/pubmed" id="30407100" target="_blank">30407100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23459282">
<a name="23459282"></a>Ogle NR, Akkerman SR. Guidance for the discontinuation or switching of antidepressant therapies in adults. <i>J Pharm Pract</i>. 2013;26(4):389-396. doi:10.1177/0897190012467210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/23459282/pubmed" id="23459282" target="_blank">23459282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20238342">
<a name="20238342"></a>Omori IM, Watanabe N, Nakagawa A, et al. Fluvoxamine versus other anti-depressive agents for depression. <i>Cochrane Database Syst Rev</i>. 2010;(3):CD006114. doi:10.1002/14651858.CD006114.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/20238342/pubmed" id="20238342" target="_blank">20238342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18460039">
<a name="18460039"></a>Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. <i>Br J Clin Pharmacol</i>. 2008;66(1):76-81. doi:10.1111/j.1365-2125.2008.03154.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/18460039/pubmed" id="18460039" target="_blank">18460039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25572308">
<a name="25572308"></a>Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastfeeding: a systematic review. <i>Hum Psychopharmacol</i>. 2015;30(1):4-20. doi:10.1002/hup.2451<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/25572308/pubmed" id="25572308" target="_blank">25572308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16415707">
<a name="16415707"></a>Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. <i>J Clin Psychopharmacol</i>. 2006;26(1):56-60. doi:10.1097/01.jcp.0000195042.62724.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/16415707/pubmed" id="16415707" target="_blank">16415707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15156966">
<a name="15156966"></a>Pass SE, Simpson RW. Discontinuation and Reinstitution of Medications During the Perioperative Period. <i>Am J Health Syst Pharm</i>. 2004;61(9):899-912.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/15156966/pubmed" id="15156966" target="_blank">15156966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26667012">
<a name="26667012"></a>Patel R, Reiss P, Shetty H, et al. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. <i>BMJ Open</i>. 2015;5(12):e008341. doi:10.1136/bmjopen-2015-008341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/26667012/pubmed" id="26667012" target="_blank">26667012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15507582">
<a name="15507582"></a>Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. <i>JAMA</i>. 2004;292(16):1969-1976. doi:10.1001/jama.292.16.1969<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/15507582/pubmed" id="15507582" target="_blank">15507582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17103176">
<a name="17103176"></a>Peiró AM, Margarit C, Torra M. Citalopram-induced Raynaud's phenomenon. <i>Rheumatol Int</i>. 2007;27(6):599-601.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/17103176/pubmed" id="17103176" target="_blank">17103176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18325859">
<a name="18325859"></a>Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. <i>Body Image</i>. 2008;5(1):13-27. doi:10.1016/j.bodyim.2007.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/18325859/pubmed" id="18325859" target="_blank">18325859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15704999">
<a name="15704999"></a>Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. <i>J Clin Psychiatry</i>. 2005;66(2):148-158. doi:10.4088/jcp.v66n0201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/15704999/pubmed" id="15704999" target="_blank">15704999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22638709">
<a name="22638709"></a>Rabenda V, Nicolet D, Beaudart C, et al. Relationship between use of antidepressants and risk of fractures: a meta-analysis. <i>Osteoporos Int</i>. 2013;24(1):121-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/22638709/pubmed" id="22638709" target="_blank">22638709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11270909">
<a name="11270909"></a>Rausch JL, Hobby HM, Shendarkar N, Johnson ME, Li J. Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis. <i>J Clin Psychopharmacol</i>. 2001;21(2):139-142. doi:10.1097/00004714-200104000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/11270909/pubmed" id="11270909" target="_blank">11270909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26156519">
<a name="26156519"></a>Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA; National Birth Defects Prevention Study. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. <i>BMJ</i>. 2015;351:h3190. doi:10.1136/bmj.h3190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/26156519/pubmed" id="26156519" target="_blank">26156519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20553304">
<a name="20553304"></a>Reeves RR, Ladner ME. Antidepressant-induced suicidality: an update. <i>CNS Neurosci Ther</i>. 2010;16(4):227-234. doi:10.1111/j.1755-5949.2010.00160.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/20553304/pubmed" id="20553304" target="_blank">20553304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23596418">
<a name="23596418"></a>Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. <i>Front Pharmacol</i>. 2013;4:45. doi:10.3389/fphar.2013.00045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/23596418/pubmed" id="23596418" target="_blank">23596418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11598429">
<a name="11598429"></a>Ricca V, Mannucci E, Mezzani B, et al. Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study. <i>Psychother Psychosom</i>. 2001;70(6):298-306. doi:10.1159/000056270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/11598429/pubmed" id="11598429" target="_blank">11598429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20443647">
<a name="20443647"></a>Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. <i>CNS Drugs</i>. 2010;24(6):501-526. doi:10.2165/11533180-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/20443647/pubmed" id="20443647" target="_blank">20443647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17242321">
<a name="17242321"></a>Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. <i>Arch Intern Med</i>. 2007;167(2):188-194. doi:10.1001/archinte.167.2.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/17242321/pubmed" id="17242321" target="_blank">17242321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8923100">
<a name="8923100"></a>Rihmer Z, Barsi J, Belsõ N, Pestality P, György S. Antidepressant-induced hypomania in obsessive-compulsive disorder. <i>Int Clin Psychopharmacol</i>. 1996;11(3):203-205. doi:10.1097/00004850-199609000-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/8923100/pubmed" id="8923100" target="_blank">8923100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22659406">
<a name="22659406"></a>Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012;51(3):606-613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/22659406/pubmed" id="22659406" target="_blank">22659406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7977878">
<a name="7977878"></a>Roose SP, Glassman AH, Attia E, et al. Comparative Efficacy of Selective Serotonin Reuptake Inhibitors and Tricyclics in the Treatment of Melancholia. <i>Am J Psychiatry</i>. 1994;151(12):1735-1739.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/7977878/pubmed" id="7977878" target="_blank">7977878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23979084">
<a name="23979084"></a>Sachs HC; Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-e809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/23979084/pubmed" id="23979084" target="_blank">23979084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16553536">
<a name="16553536"></a>Safer DJ and Zito JM. Treatment Emergent Adverse Effects of Selective Serotonin Reuptake Inhibitors by Age Group: Children vs. Adolescents,” <i>J Child Adolesc Psychopharmacol</i>. 2006,16(1/2):159-169.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/16553536/pubmed" id="16553536" target="_blank">16553536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27834194">
<a name="27834194"></a>Samuel NG, Seifert CF. Risk of bleeding in patients on full-dose enoxaparin with venous thromboembolism and selective serotonin reuptake inhibitors. <i>Ann Pharmacother</i>. 2017;51(3):226-231. doi:10.1177/1060028016677309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/27834194/pubmed" id="27834194" target="_blank">27834194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16683860">
<a name="16683860"></a>Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>J Clin Psychiatry</i>. 2006;67(suppl 4):27-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/16683860/pubmed" id="16683860" target="_blank">16683860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32238008">
<a name="32238008"></a>Schoretsanitis G, Spigset O, Stingl JC, Deligiannidis KM, Paulzen M, Westin AA. The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. <i>Expert Opin Drug Metab Toxicol</i>. 2020;16(5):431‐440. doi:10.1080/17425255.2020.1750598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/32238008/pubmed" id="32238008" target="_blank">32238008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19440080">
<a name="19440080"></a>Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. <i>J Clin Psychopharmacol</i>. 2009;29(3):259-266. doi:10.1097/JCP.0b013e3181a5233f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/19440080/pubmed" id="19440080" target="_blank">19440080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15014601">
<a name="15014601"></a>Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/15014601/pubmed" id="15014601" target="_blank">15014601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31035856">
<a name="31035856"></a>Slomian J, Honvo G, Emonts P, Reginster JY, Bruyère O. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. <i>Womens Health (Lond)</i>. 2019;15:1745506519844044. doi:10.1177/1745506519844044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/31035856/pubmed" id="31035856" target="_blank">31035856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9241009">
<a name="9241009"></a>Spigset O, Mjorndal T. The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status. <i>J Clin Psychopharmacol</i>. 1997;17(4):292-297. doi:10.1097/00004714-199708000-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/9241009/pubmed" id="9241009" target="_blank">9241009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16633143">
<a name="16633143"></a>Spivak B, Strous RD, Shaked G, Shabash E, Kotler M, Weizman A. Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. <i>J Clin Psychopharmacol.</i> 2006;26(2):153-156. doi:10.1097/01.jcp.0000203195.65710.f0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/16633143/pubmed" id="16633143" target="_blank">16633143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26204124">
<a name="26204124"></a>Sriraman NK, Melvin K, Meltzer-Brody S. ABM Clinical Protocol #18: Use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/26204124/pubmed" id="26204124" target="_blank">26204124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10333979">
<a name="10333979"></a>Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. <i>J Affect Disord</i>. 1998;51(3):215-235. doi:10.1016/s0165-0327(98)00221-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/10333979/pubmed" id="10333979" target="_blank">10333979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14604447">
<a name="14604447"></a>Stein DJ, Westenberg HG, Yang H, et al. Fluvoxamine CR in the Long-Term Treatment of Social Anxiety Disorder: The 12- to 24-Week Extension Phase of a Multicentre, Randomized, Placebo-Controlled Trial. <i>Int J Neuropsychopharmacol</i>. 2003;6(4):317-323.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/14604447/pubmed" id="14604447" target="_blank">14604447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18628446">
<a name="18628446"></a>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. doi:10.1345/aph.1L066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/18628446/pubmed" id="18628446" target="_blank">18628446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18759711">
<a name="18759711"></a>Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. <i>Expert Opin Drug Saf</i>. 2008;7(5):587-596. doi:10.1517/14740338.7.5.587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/18759711/pubmed" id="18759711" target="_blank">18759711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19254516">
<a name="19254516"></a>Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. <i>J Clin Psychiatry</i>. 2009;70(3):344-353. doi:10.4088/jcp.07m03780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/19254516/pubmed" id="19254516" target="_blank">19254516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19491861">
<a name="19491861"></a>Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2009;104(6):1475-1482. doi:10.1038/ajg.2009.128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/19491861/pubmed" id="19491861" target="_blank">19491861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16779744">
<a name="16779744"></a>Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. <i>Clin Infect Dis. </i>2006a;43(2):180-187. doi:10.1086/504809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/16779744/pubmed" id="16779744" target="_blank">16779744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17088502">
<a name="17088502"></a>Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. <i>Arch Gen Psychiatry</i>. 2006b;63(11):1217-1223. doi:10.1001/archpsyc.63.11.1217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/17088502/pubmed" id="17088502" target="_blank">17088502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28766108">
<a name="28766108"></a>Tomlin AM, Reith DM, Woods DJ, et al. A pharmacoepidemiology database system for monitoring risk due to the use of medicines by New Zealand primary care patients. <i>Drug Saf</i>. 2017;40(12):1259-1277. doi:10.1007/s40264-017-0579-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/28766108/pubmed" id="28766108" target="_blank">28766108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19958306">
<a name="19958306"></a>Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. <i>Acta Psychiatr Scand</i>. 2010;121(6):404-414. doi:10.1111/j.1600-0447.2009.01514.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/19958306/pubmed" id="19958306" target="_blank">19958306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25896469">
<a name="25896469"></a>Uguz F. Gastrointestinal side effects in the baby of a breastfeeding woman treated with low-dose fluvoxamine. <i>J Hum Lact</i>. 2015;31(3):371-373.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/25896469/pubmed" id="25896469" target="_blank">25896469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15906018">
<a name="15906018"></a>van Geffen EC, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts AC. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. <i>Eur J Clin Pharmacol</i>. 2005;61(4):303-307. doi:10.1007/s00228-005-0921-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/15906018/pubmed" id="15906018" target="_blank">15906018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8453824">
<a name="8453824"></a>van Harten J, Duchier J, Devissaguet JP, van Bemmel P, de Vries MH, Raghoebar M. Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. <i>Clin Pharmacokinet</i>. 1993;24(2):177-182. doi:10.2165/00003088-199324020-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/8453824/pubmed" id="8453824" target="_blank">8453824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27663940">
<a name="27663940"></a>Varigonda AL, Jakubovski E, Bloch MH. Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2016;55(10):851-859.e2. doi:10.1016/j.jaac.2016.07.768<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/27663940/pubmed" id="27663940" target="_blank">27663940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18219438">
<a name="18219438"></a>Vestergaard P, Rejnmark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. <i>Calcif Tissue Int</i>. 2008;82(2):92-101. doi:10.1007/s00223-007-9099-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/18219438/pubmed" id="18219438" target="_blank">18219438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30775508">
<a name="30775508"></a>Wadhwa R, Kumar M, Talegaonkar S, Vohora D. Serotonin reuptake inhibitors and bone health: a review of clinical studies and plausible mechanisms. <i>Osteoporos Sarcopenia</i>. 2017;3(2):75-81. doi:10.1016/j.afos.2017.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/30775508/pubmed" id="30775508" target="_blank">30775508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26003261">
<a name="26003261"></a>Waldinger MD. Psychiatric disorders and sexual dysfunction. <i>Handb Clin Neurol</i>. 2015;130:469-489. doi:10.1016/B978-0-444-63247-0.00027-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/26003261/pubmed" id="26003261" target="_blank">26003261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16913164">
<a name="16913164"></a>Warner, CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74:449-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/16913164/pubmed" id="16913164" target="_blank">16913164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15169695">
<a name="15169695"></a>Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. <i>Am J Psychiatry</i>. 2004;161(6):1066-1078. doi:10.1176/appi.ajp.161.6.1066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/15169695/pubmed" id="15169695" target="_blank">15169695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14709947">
<a name="14709947"></a>Westenberg HG, Stein DJ, Yang H, et al. A Double-Blind Placebo-Controlled Study of Controlled Release Fluvoxamine for the Treatment of Generalized Social Anxiety Disorder. <i>J Clin Psychopharmacol</i>. 2004;24(1):49-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/14709947/pubmed" id="14709947" target="_blank">14709947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28708853">
<a name="28708853"></a>Westin AA, Brekke M, Molden E, Skogvoll E, Spigset O. Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition. <i>PLoS One</i>. 2017;12(7):e0181082. doi:10.1371/journal.pone.0181082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/28708853/pubmed" id="28708853" target="_blank">28708853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29873955">
<a name="29873955"></a>Williams AJ, Lai Z, Knight S, Kamali M, Assari S, McInnis MG. Risk factors associated with antidepressant exposure and history of antidepressant-induced mania in bipolar disorder. <i>J Clin Psychiatry</i>. 2018;79(3):17m11765. doi:10.4088/JCP.17m11765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/29873955/pubmed" id="29873955" target="_blank">29873955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8101329">
<a name="8101329"></a>Wolkenstein P, Revuz J, Diehl JL, Langeron O, Roupie E, Machet L. Toxic epidermal necrolysis after fluvoxamine. <i>Lancet</i>. 1993;342(8866):304-305. doi:10.1016/0140-6736(93)91852-d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/8101329/pubmed" id="8101329" target="_blank">8101329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28953843">
<a name="28953843"></a>Womersley K, Ripullone K, Agius M. What are the risks associated with different selective serotonin re-uptake inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence. <i>Psychiatr Danub</i>. 2017;29(suppl 3):629-644.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/28953843/pubmed" id="28953843" target="_blank">28953843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10753007">
<a name="10753007"></a>Wylie ME, Miller MD, Shear MK, et al. Fluvoxamine pharmacotherapy of anxiety disorders in later life: preliminary open-trial data. <i>J Geriatr Psychiatry Neurol</i>. 2000;13(1):43-48. doi:10.1177/089198870001300107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/10753007/pubmed" id="10753007" target="_blank">10753007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9171475">
<a name="9171475"></a>Wynn RL. New antidepressant medications. <i>Gen Dent</i>. 1997;45(1):24-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/9171475/pubmed" id="9171475" target="_blank">9171475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34381508">
<a name="34381508"></a>Xuev S, Ickowicz A. Serotonin syndrome in children and adolescents exposed to selective serotonin reuptake inhibitors - a review of literature. <i>J Can Acad Child Adolesc Psychiatry</i>. 2021;30(3):156-164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/34381508/pubmed" id="34381508" target="_blank">34381508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19701065">
<a name="19701065"></a>Yonkers KA, Wisner KL, Stewart DE, et al. The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists. <i>Obstet Gynecol</i>. 2009;114(3):703-713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/19701065/pubmed" id="19701065" target="_blank">19701065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36460460">
<a name="36460460"></a>Zhang F, Gong W, Cui Z, Li J, Lu Y. Rhabdomyolysis in a male adolescent associated with monotherapy of fluvoxamine. <i>Eur J Hosp Pharm</i>. 2022;ejhpharm-2022-003533. doi:10.1136/ejhpharm-2022-003533<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluvoxamine-pediatric-drug-information/abstract-text/36460460/pubmed" id="36460460" target="_blank">36460460</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13025 Version 402.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
